Haplotype-aware single-cell multiomics uncovers functional effects of somatic structural variation

Hyobin Jeong^{1,2,3,4}, Karen Grimes^{1,2,3,4}, Peter-Martin Bruch^{3,4}, Tobias Rausch^{1,4}, Patrick Hasenfeld¹, Radhakrishnan Sabarinathan⁵, David Porubsky^{6,7,8}, Sophie A. Herbst^{3,4}, Büşra Erarslan-Uysal⁴, Johann-Christoph Jann⁸, Tobias Marschall⁹, Daniel Nowak⁸, Jean-Pierre Bourquin¹⁰, Andreas E. Kulozik^{4,11}, Sascha Dietrich^{3,4,12}, Beat Bornhauser¹⁰, Ashley D. Sanders^{1,13,14,15,*}, Jan O. Korbel^{1,4,*}

¹European Molecular Biology Laboratory, Genome Biology Unit, Meyerhofstr. 1, Heidelberg, Germany

²Joint PhD degree from EMBL and Heidelberg University, Faculty of Biosciences, Heidelberg, Germany

³Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, Heidelberg

⁴Molecular Medicine Partnership Unit, European Molecular Biology Laboratory, University of Heidelberg, Heidelberg, Germany

⁵National Centre for Biological Sciences, Tata Institute of Fundamental Research, Bangalore, Karnataka, India

⁶Center for Bioinformatics, Saarland University, Saarbrücken, Germany

⁷Max Planck Institute for Informatics, Saarbrücken, Germany

⁸Department of Hematology and Oncology, Medical Faculty Mannheim of the Heidelberg University, Germany

⁹Heinrich Heine University, Medical Faculty, Institute for Medical Biometry and Bioinformatics, Moorenstr. 20, Düsseldorf, Germany

¹⁰Division of Pediatric Oncology, University Children's Hospital, Zürich, Switzerland

¹¹Department of Pediatric Oncology, Hematology, and Immunology, University of Heidelberg and Hopp Children's Cancer Center, Heidelberg, Germany

¹²Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany

¹³Berlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany

¹⁴Berlin Institute of Health (BIH), Berlin, Germany

¹⁵Charité-Universitätsmedizin, Berlin, Germany

[%]Present address: Dept. of Genome Sciences, University of Washington School of Medicine, Seattle, WA, USA

[#]Joint first authors; ^{*}joint senior authors. Correspondence: Ashley.Sanders@mdc-berlin.de, Jan.Korbel@embl.org

Abstract

Somatic structural variants (SVs) are widespread in cancer genomes, however, their impact on tumorigenesis and intra-tumour heterogeneity is incompletely understood, since methods to functionally characterize the broad spectrum of SVs arising in cancerous single-cells are lacking. We present a computational method, scNOVA, that couples SV discovery with nucleosome occupancy analysis by haplotype-resolved single-cell sequencing, to systematically uncover SV effects on *cis*-regulatory elements and gene activity. Application to leukemias and cell lines uncovered SV outcomes at several loci, including dysregulated cancer-related pathways and mono-allelic oncogene expression near SV breakpoints. At the intra-patient level, we identified different yet overlapping subclonal SVs that converge on aberrant Wnt signaling. We also deconvoluted the effects of catastrophic chromosomal rearrangements resulting in oncogenic transcription factor dysregulation. scNOVA directly links SVs to their functional consequences, opening the door for single-cell multiomics of SVs in heterogeneous cell populations.

Introduction

The mutational landscapes of numerous cancers have recently been catalogued in pan-cancer surveys^{1,2}, revealing that ~55% of somatic driver mutations represent SVs, which outnumber base-pair substitutions as cancer drivers². Somatic SVs drive tumor development, progression and therapy resistance, and cause inter- and intra-tumor heterogeneity³⁻⁸. Somatic DNA rearrangement processes generate a broad spectrum of SV classes, which range from simple SVs such as deletions and inversions to catastrophic rearrangement classes resulting from chromothripsis, chromoplexy and breakage-fusion bridge (BFB) cycles⁹⁻¹³. However, with the exception of focal gene deletions and amplifications, the functional effects of SVs are understudied^{1,2,6,14,15}. Indeed, the impact of SVs often escapes attention as gene panels, exomes and genomes sequenced with moderate coverage suffer from low SV discovery sensitivity, especially for subclonal SVs^{1,2}, which restrains applications in precision oncology. Computational methods integrating bulk-cell RNA-seq and cancer genome sequencing data have been employed to infer the functional outcomes of a wider spectrum of SVs¹⁴⁻¹⁷. These methods, however, have several limitations: They require generation of large cohorts with paired RNA-seq and genomic data to analyse recurrent SVs, which limits their routine use, or they are restricted to studying SVs that result in allele-specific outlier expression in a tumour sample¹⁴⁻¹⁷. Furthermore, intra-tumour heterogeneity is not taken into account by these methods, which are therefore essentially restricted to the main clone.

Unambiguous inference that a somatic mutation mediates an effect can be drawn by measuring both genotypes and molecular phenotypes in the same cell, a feat realizable by single-cell multiomics methods¹⁸⁻²². These methods allow investigating the functional impact of mutations in genetically heterogeneous contexts, for example, by coupling single-cell DNA and RNA sequencing. Several methods have been developed¹⁸⁻²¹, but all present methods cover only a small subset of the spectrum of SVs arising in cancer: chromosome-arm level changes, and interstitial as well as terminal somatic copy-number alterations (SCNAs) greater than 10 Megabase (Mb) in size, which jointly represent only 37% of SV drivers seen in a typical cancer genome². SCNAs smaller than 10Mb, as well as translocations, balanced inversions, and complex rearrangement classes^{9,10,12,23} – which together account for the majority of driver SVs² – escape detection with these methods.

Here, we describe scNOVA (for single-cell Nucleosome Occupancy and Genetic Variation Analysis), a method to dissect the full spectrum of somatic SVs $\geq 200\text{kb}$ in size by inferring their functional consequences using single-cell multiomics principles. scNOVA leverages data from template-strand sequencing (Strand-seq²⁴), a haplotype-resolved single-cell technique, in two orthogonal ways: [i] it uses the specific DNA fragmentation pattern resulting from Micrococcal nuclease (MNase) digestion of Strand-seq libraries to directly measure nucleosome occupancy (NO) and indirectly infer *cis*-regulatory element (CRE) accessibility²⁵⁻²⁷ in each cell, and [ii] it couples this ‘molecular phenotype proxy’ with SV discovery by single-cell tri-channel processing (scTRIP), via joint modeling of read-orientation, read-depth, and haplotype-phase²⁸ – in the same individual cell. MNase digests linker DNA between nucleosomes, while nucleosome-protected DNA (or DNA protected by some other strongly bound proteins) remains intact, allowing inference of NO along the genome by interpreting sequence read counts^{25-27,29}. Prior work has shown how nucleosome positioning and occupancy reflects gene regulation, with active enhancers exhibiting decreased NO, and with actively transcribed genes showing reduced NO at the transcriptional start and termination sites, as well as reduced nucleosome packing within the gene body^{25-27,29-31}. However, the relationships between NO and somatic mutational landscapes in cancer cells are unexplored. scNOVA addresses this by integrating somatic SVs and NO measurements in the same cell – in a haplotype-resolved manner – to dissect the functional impact of somatic SVs in genetically heterogeneous samples. Using scNOVA, we functionally deconvolute a wide variety of SVs in single cells providing insights into their functional outcomes, including complex DNA rearrangements that previously resisted comprehensive characterization.

Results

Haplotype-aware NO reveals changes in CREs, cell types, and differential gene activity in Strand-seq data
Resemblance of Strand-seq and MNase-based NO tracks. Using Strand-seq, a technique in which non-template strands are labeled during DNA replication using Bromodeoxyuridine (BrdU)²⁴, we recently reported comprehensive SV discovery in single cells at 200kb resolution²⁸. We next sought to investigate the functional outcomes of these SVs in individual cellular genomes by single-cell multiomics. We hypothesized that NO

patterns derived from MNase cuts made during Strand-seq library preparation²⁴ would represent a promising readout, allowing to couple SV discovery with a data type equivalent to single-cell MNase-seq data²⁶ – to link somatic SVs and NO profiles in the same cell (**Fig. 1a, Fig. S1**). To address our hypothesis, we first assessed the suitability of Strand-seq for revealing nucleosome locations, by comparing Strand-seq to bulk MNase-seq data generated for the NA12878 lymphoblastoid cell line (LCL). Each high-quality Strand-seq library ($N=95$ single cells) was sequenced to a median of 540,379 mapped non-duplicate read pairs³², which amounts to $\sim 0.018\times$ coverage per cell (**Table S1**). To directly compare Strand-seq with bulk-cell MNase-seq data³³, we pooled these Strand-seq data into “pseudo-bulk” tracks, and then measured NO along the genome (**Methods**). We found Strand-seq and MNase-seq were highly concordant in terms of uniformity of coverage and inferred nucleosome positions at DNase-I hypersensitive sites (Spearman's $r=0.68$) (**Fig. 1b,c**). Measuring NO genome-wide at the binding sites of CTCF³⁴ (a key chromatin organizer) revealed a nucleosome-depleted region at the center of the binding site in the Strand-seq track, as previously reported for MNase-seq²⁹ (**Fig. S2**), and nucleosome positioning near CTCF sites^{26,29} closely matched between Strand-seq and MNase-seq (**Fig. 1d**). Nucleosome repeat length²⁹ estimates were consistent between independent Strand-seq experiments ($195.4 \pm 0.4\text{bp}$) and concordant with bulk MNase-seq ($193.7 \pm 0.6\text{bp}$) (**Fig. S2**), showing these patterns are reproducible. In addition, both assays measured NO in all fifteen chromatin states identified by the Roadmap Epigenome Consortium³⁵. Among these chromatin states, Strand-seq and MNase-seq revealed the highest NO signals on average for the polycomb-repressed state and the bivalent enhancer state, whereas the lowest average NO signals were consistently seen for the active transcription start site (TSS) state (**Fig. S3**). This indicates that Strand-seq based NO tracks closely resemble those derived using classical MNase-seq^{26,29}, and we thus concluded that Strand-seq data enable direct measurement of NO in single cells.

scNOVA reveals haplotype-specific CRE accessibility. Encouraged by these observations, we developed scNOVA, a computational framework that harnesses Strand-seq data to measure NO genome-wide within a cell, and couples this readout with SVs discovered in the same cell to functionally characterize SV landscapes (**Fig. 1a**). Given that Strand-seq data are haplotype-resolved by nature³², we hypothesized we could identify haplotype-specific differences in nucleosome occupancy (in short: haplotype-specific NO) – which may, for example, arise as a result of a germline genetic variant or a somatic mutation present on one of the chromosomal homologues. To address this, we performed analyses of haplotype-specific NO at 66,254 CREs previously defined³⁶ in NA12878. First, we phased 24,652,658/49,205,197 (50.1%) of the Strand-seq read fragments onto chromosomal haplotypes, and pooled these reads to generate phased pseudo-bulk NO tracks for each of the two haplotypes (denoted ‘H1’ and ‘H2’; **Fig. 1b**). Using these phased NO tracks, we then employed scNOVA to test for haplotype-specific NO within a 1 kilobase (kb) region centred around each CRE (**Fig. S4**). This analysis showed haplotype-specific NO at 727 out of 66,254 CREs (Exact test) when controlling the false discovery rate (FDR) at 10%. These 727 CREs were 1.4-fold enriched on chromosome X ($P=0.019$; hypergeometric test), presumably due to the X-inactivation process³⁷ operating in the female-derived NA12878 cell line (**Fig. S5**). We next investigated whether haplotype-specific NO at CREs reflects allele-specific gene expression, by using bulk RNA-seq data³⁴ that we phased using the Strand-seq haplotypes as a guide (**Methods**). After assigning putative target genes for each CRE based on the nearest gene approach³⁸, genes targeted by CREs with haplotype-specific NO showed a significant proclivity to be allele-specifically expressed (**Fig. S4**; $P=0.0021$; hypergeometric test; 1.5-fold enrichment). A CRE inferred to target the *NFIB* gene, for example, exhibited a clear pattern of haplotype-specific NO: in this CRE, phased NO reads were exclusively assigned to H2, indicating increased CRE accessibility on H1 (**Fig. 1e**; Exact test; 10% FDR), and this was coupled with mono-allelic *NFIB* expression from the H1 haplotype (**Fig. 1e**; FDR-adjusted $P<2.3\text{E-}10$; likelihood ratio test). Likewise, a CRE targeting *WWC3*, a gene subject to X-inactivation, demonstrated absence of NO on H2 (10% FDR) – the active chromosome X – coupled with mono-allelic *WWC3* expression from H2 (**Fig. S5**; FDR-adjusted $P<2.5\text{E-}40$). These data suggest that scNOVA enables haplotype-phased NO measurements, with haplotype-specific NO patterns at CREs reflecting target gene expression patterns on individual homologues.

Cell-type classification by NO profiling. Since NO within gene bodies reflects gene activity²⁹, we further hypothesized that we could use NO tracks derived from Strand-seq to infer cell types based on interpreting the activity of lineage-specific genes. In order to address this, we first tested whether Strand-seq based NO profiles at

gene bodies reflect global gene expression patterns of a cell. We pooled 33 Million fragments (including phased and unphased reads) from 79 Strand-seq libraries generated for the retinal pigment epithelial-1 (RPE-1) cell line²⁸, and then used bulk RNA-seq data for the same line to measure NO at actively expressed versus silent gene bodies. Analysis of these pseudo-bulk NO data revealed a strong inverse correlation between NO at gene bodies and bulk gene expression ($P < 2.2 \times 10^{-16}$; Spearman's r of up to -0.24; **Fig. 1f, Fig. S6**), where highly expressed genes showed lower NO within their gene bodies (and *vice versa*), consistent with prior MNase-seq based findings²⁹. We next explored the utility of NO for cell type classification, by implementing a multivariate dimensionality-reduction framework into scNOVA. We performed *in silico* mixing of Strand-seq libraries generated for different LCLs and RPE cell lines, and built a classifier (**Methods**) that separates distinct cell types by partial least squares discriminant analysis (**Fig. S7**). We first used a training set of 179 mixed libraries, and initially considered 19,629 features, which reflects ENSEMBL³⁹ gene bodies with detectable Strand-seq reads to allow for NO measurements. After feature selection, 1,738 features were retained in the final model. We then used a non-overlapping set of 123 single cells to assess performance, all of which scNOVA classified accurately (area under the curve (AUC)=1; **Fig. S7**). We also successfully discriminated between cells from three highly-related RPE cell lines (RPE-1, BM510 and C7), which all originate from the same donor, but which underwent distinct genome instability and selection trajectories^{28,40} (AUC=0.96; **Fig. 1g, Fig. S7**). Thus, scNOVA enables accurate cell type classification based on NO, even amongst closely related cells, indicating that it can be applied to heterogeneous cell samples.

Inferring gene activity changes in pseudo-clones. Having confirmed that genome-wide NO measurements can be used to distinguish cell types, we next tested whether NO at gene bodies is also suited to infer changes in the activity of individual genes. Such functionality would be potentially highly relevant for applying scNOVA in cancers that show dysregulated cancer-related gene expression in distinct subclones¹⁷. Integrating deep convolutional neural networks (CNNs) and negative binomial generalized linear models (**Fig. S8, S9**), we hence devised an scNOVA module to predict gene activity changes between defined cell populations (*i.e.* subclones) using NO tracks. To define the ground truth of gene expression, we used bulk RNA-seq data generated for distinct cell lines. Then, to parameterize scNOVA, we mixed different numbers of Strand-seq libraries from these cell lines *in silico* to create “pseudo-clones”, and performed benchmarking to assess the ability of scNOVA to predict changes in gene activity between pseudo-clones (each composed of cells from a single cell line) by analyzing NO at gene bodies (**Fig. S10, S11**). Indeed, scNOVA's differential gene activity score (**Methods**) was highly predictive of the 10 most differentially expressed genes, where analyses of pseudo-clones comprising 156 RPE-1 and 46 HG01573 (LCL) libraries revealed an AUC of 0.93 (AUC=0.88 for the 50 most differentially expressed genes; see **Fig. 1h**). Gene activity changes inferred included well-known markers of epithelial (*e.g.* *EGFR*, *VCAN*) and lymphoid (*e.g.* *CD74*, *CD100*) cell lineages (**Table S2**). When controlling the FDR at 10%, 10/10 (100%) of the most overexpressed genes in RPE-1, as well as 7/10 (70%) of the most overexpressed genes in HG01573 were correctly captured by scNOVA. scNOVA made informative predictions even when we performed *in silico* cell mixing to simulate minor subclones present with a very low cell fraction (CF) of only 30 cells (CF=20%), 8 cells (CF=5%), and 2 cells (CF=1.3%), respectively, resulting in AUCs of 0.92, 0.79, 0.68. When cell fractions were smaller than 10%, we found that an alternative mode of scNOVA (**Methods**) that uses partial least squares discriminant analysis (PLS-DA) to infer gene activity changes provides slightly improved performances (with AUCs reaching 0.90, 0.82, 0.70 for CFs of 20%, 5%, and 1.3%, respectively; **Fig S11**). We also created pseudo-clones from RPE cells, represented by 156 RPE-1 cells (the original hTERT-immortalised cell line) and 154 C7 cells (which underwent transformation)⁴⁰, where we measured an AUC of 0.73 (**Fig. S10**). Comparing these related lines, scNOVA inferred 615 genes to increase in activity in C7, which included several cancer-related genes (*e.g.* *CDK1*, *EEF1A2*), and amongst those 615 genes “carcinoma” represented the most enriched functional category (**Table S2**) – in line with the transformed status of C7. We concluded that scNOVA enables accurate inference of gene activity changes based on analyzing Strand-seq-derived NO tracks. Using these inferred gene activity changes as a proxy for molecular phenotypes, together with single-cell SV discovery, we next sought to investigate the functional outcomes of somatic SV landscapes.

Benchmarking scNOVA: functional outcomes of somatic SV landscapes in lymphoblastoid cell lines

Benchmarking in cell lines. Before turning to patient samples, we first benchmarked the coupling of SV calling and NO analysis – in the same individual cell – using cell lines. We used $N=25$ LCLs generated from diverse 1000

Genomes Project (1KGP) samples, which were recently subjected to Strand-seq by the Human Genome Structural Variation Consortium to construct a haplotype-resolved germline SV resource⁴¹. Single-cell SV discovery in 1,372 Strand-seq libraries (**Table S1**) revealed extensive intra-sample genetic heterogeneity in these widely used cell lines: We detected 205 somatic SVs overall, with 24/25 (96%) LCLs showing at least one somatic SV – a 7-fold increase in the proportion of LCLs exhibiting somatic heterogeneity compared to a prior report⁴² (**Table S3, Supplementary Data**). A significant subset of these somatic SVs were present at high clonality (with >10% CF), affecting 13/25 LCLs. These high-clonality SVs, unexpectedly, included novel subclonal SV in NA12878, arguably the most widely sequenced human cell line^{34,43,44} – which showed a previously not described 500kb somatic 19q13.12 deletion seen with CF=21%, along with two mutually exclusive 22q11.2 somatic deletions (with CFs of 21% and 57%, respectively; **Fig. S12, S13**). The 22q11.2 events map to the known site of IGL recombination, a somatic rearrangement occurring during normal B cell development and thought to have little transcriptional consequences⁴⁵. Thus, we focused on the 19q13.12 event, which led to the loss of a copy of *ZNF382* – a known tumor suppressor and repressor of c-Myc⁴⁶. Application of scNOVA revealed significantly increased activity of *ERCC6*, notably a target of c-Myc/Max dimers⁴⁷, in cells harboring the somatic deletion (10% FDR; **Table S2**).

We sought to validate this finding using orthogonal datasets, by reanalyzing Fluidigm and Smart-seq single-cell RNA-seq (scRNA-seq) data previously generated in NA12878^{48,49}. We subjected these datasets to an array of computational tools for SCNA discovery from scRNA-seq data (InferCNV⁵⁰, HoneyBADGER⁵¹ and CONICSm⁵²), none of which identified SCNAs affecting 19q13.12 or 22q11.2 (**Table S4**). This might not be surprising, as these somatic deletions comprised only 11 and 12 expressed genes, respectively – fewer than the recommended number of genes (*i.e.* 100) for confident SCNA calling using scRNA-seq⁵². We therefore attempted to detect these somatic deletions in a targeted manner (by “genotyping”), via inputting the high-resolution SV breakpoint coordinates from our framework into CONICSm. We tested different CONICSm posterior probability cutoffs⁵² to explore SCNA genotyping in the context of a low number of expressed genes (**Fig. S13**). This analysis inferred the presence of the 19q13.12 somatic deletion in NA12878 across a wide range of CONICSm posterior probability cutoffs (**Fig. S13**). We next performed differential expression analysis between subclones composed of cells with high-confidence deletion genotypes, which revealed that *ERCC6* is over-expressed in cells harboring the 19q13.12 somatic deletion, thus verifying the prediction made by scNOVA (10% FDR, **Fig. S13**). Additionally, cells harboring the 19q13.12 deletion showed several dysregulated signaling pathways compared to cells not exhibiting this event, which included the dysregulation of c-Myc/Max targets and aberrant MAPK signaling (10% FDR, **Fig. S13**). These results suggest that scNOVA is able to leverage SVs inaccessible to scRNA-seq based discovery to dissect the functional effects of these variants – either directly using NO based inference, or by leveraging high-resolution breakpoint assignments from our framework for targeted identification of SCNAs (that would otherwise escape detection) in scRNA-seq data.

Complex subclonal rearrangements resulting in dysregulated MAPK signaling. Encouraged by these somatic SV data in NA12878, we next turned our attention to NA20509, the LCL with the most abundant SV subclone (85% CF). SVs discovered in this subclone included complex rearrangements that appeared to affect two chromosomes, providing a relevant use case since Strand-seq enables the identification of subclonal complex and inter-chromosomal SVs inaccessible to discovery by other methods²⁸. Analyses of these somatic SVs revealed a 49Mb dispersed duplication on 5q, and a 2.5Mb inverted duplication on 17p with an adjacent terminal deletion on the same haplotype – a signature characteristic of the single cell footprint defined²⁸ for BFB rearrangements (**Fig. 2a**). We next pursued a translocation analysis²⁸, which revealed that the rearranged 5q and 17p segments were fused into a ~115Mb derivative chromosome (**Fig. S14**), reflecting a common mechanism through which BFBs can be stabilised. Bulk whole genome paired-end sequencing (WGS) validated these subclonal somatic rearrangements in a separate NA20509 cell stock⁵³, with ~30% CF (**Fig. S14**). Using scNOVA, we inferred that 18 genes were dysregulated in the BFB subclone (**Fig. 2b**). None of these genes reside in the genomic segments affected by the somatic DNA rearrangements, suggesting that the gene activity changes arose from gene regulatory effects in *trans*. To further characterize the functional consequences of these *trans* effects, we devised an scNOVA module to test for the overrepresentation of functionally-related gene sets⁵⁴, such as transcription factor (TF) targets (**Methods**). Using this module, we observed that the dysregulated genes inferred in the BFB subclone were

enriched for the downstream targets of c-Myc and Max (10% FDR, **Fig. 2c**). These two TFs form heterodimers to regulate cell proliferation in the MAPK signaling cascade^{55,56}, which is the same pathway we previously associated with the somatic 19q13.12 deletion in NA12878. Indeed, we observed that *MAP2K3*, a MAPK signaling pathway member that activates c-Myc/Max via p38^{57,58}, is located in the center of the BFB-mediated inverted duplication on the derivative chromosome (**Fig. 2a**), likely resulting in *MAP2K3* dosage increase. Consistent with these observations, analysis of bulk RNA-seq data available for 24 of these LCLs⁴¹ showed that NA20509 exhibits the highest *MAP2K3* expression, and the highest c-Myc/Max target expression, amongst the entire LCL panel (**Fig. S15, Fig. 2d**). Additionally, haplotype-resolved RNA-seq analysis in NA20509 (**Methods**) revealed mono-allelic expression of *MAP2K3* restricted to the complex derivative chromosome haplotype ($P=1.8e-73$; FDR-adjusted likelihood ratio test; **Fig. 2e**), indicating that only the somatically rearranged haplotype exhibits *MAP2K3* activity. Collectively, these data orthogonally support the predictions of our scNOVA framework that a complex BFB-mediated rearrangement in NA20509 leads to activation of the c-Myc/Max pathway (model shown in **Fig. 2c**). These findings showcase scNOVA's ability to predict global gene activity outcomes associated with a subclonal SV, allowing us to now functionally characterize somatic SV landscapes in patient samples.

Haplotype-specific functional outcomes of somatic DNA rearrangements in leukemia

Subclonal SVs in a chronic lymphocytic leukemia (CLL) primary patient sample. Encouraged by this benchmarking exercise, we next applied scNOVA to functionally dissect leukemia samples. We first analysed primary B-cells from a 61-year-old CLL patient (CLL_24). Routine clinical cytogenetics did not show any prototypical genomic alteration⁵⁹ in CLL_24. By contrast, our single-cell analysis of 86 Strand-seq libraries revealed extensive cellular heterogeneity; in this single leukemia sample, we identified 11 different karyotypes represented by 13 SVs occurring at CFs between 1-5% (**Table S3**). While these CF levels are readily amenable to Strand-seq, they are considered to be below the detection limit of WGS²⁸. Consequently, our approach detected a higher number of somatic subclones for CLL_24 than for any CLL patient sample subjected to WGS by the International Cancer Genome Consortium (ICGC)³. Chromosome 10q24 showed especially pronounced subclonal heterogeneity; here, 7 independent and partially overlapping hemizygous deletions were found, ranging from 2-31Mb in size, and clustering proximal to the chromosome fragile site *FRA10B*⁶⁰ (**Fig. 3a, Fig. S16**). Overlap analysis of the deletions revealed a 1.4 Mb 'minimal segment' at 10q24.32 that was lost in 11 different cells, and occurred independently on both haplotypes (**Fig. 3b**), confirming somatic 10q24 deletions arose multiple times in this patient. Prior studies reported somatic 10q24 deletions in 1-4% of CLLs⁶¹⁻⁶³, which showed enrichment in relapsed/refractory and high-risk cases⁶⁴, suggesting this SV represents a somatic driver. We furthermore verified this deletion in two independent cohorts, where we detected somatic 10q24.32 deletions in 6/306 (2%) CLLs from the ICGC cohort analyzed by SNP arrays⁶² and 4/96 (4%) CLLs from the Pan-Cancer Analysis of Whole Genomes (PCAWG) cohort analyzed by WGS² (**Fig. 3b, Fig. S19**). It has been proposed that loss of *NFKB2*, present in the minimal segment, may be responsible for the driver phenotype⁶⁵, but a molecular analysis of the consequences of this somatic SV has been lacking. We therefore sought to characterise the functional consequences of 10q24.32 deletions arising in CLL_24.

Sub-clonal functional consequences of different 10q24.32 deletions. Having learned that the recurrent 10q24.32 deletion is subclonal in CLL_24 now provides an opportunity to directly compare the phenotypes of cells with and without the deletion and explore the molecular consequences of the somatic SV in (nearly) isogenic subclones. We applied scNOVA and identified three differentially active genes: *GPA33*, *ARSK* and *DNM2*, which we found dysregulated in a joint comparison of the eleven 10q24.32 deletion-bearing cells with the remaining 75 cells (10% FDR; **Fig. 3c, Fig. S17**). Notably, all of these genes reside on other chromosomes. For instance, in cells harboring the deletion we observed reduced NO at the *DNM2* locus on chromosome 19, indicating increased activity of Dynamin 2, a GTP-binding protein previously shown to be overexpressed⁶⁶ in other leukemias (**Fig. 3d**). Given these observed *trans* effects, we next performed a molecular phenotyping analysis similar to the NA20509 case, with the aim to measure global expression outcomes associated with the 10q24 deletion. Since three differentially active genes (**Fig. 3c**) are too few for a gene set overrepresentation analysis, we instead used scNOVA to jointly model NO at gene bodies across gene sets from MSigDB⁶⁷, an approach that is more sensitive since single genes not reaching significance on their own can contribute to the joint model as a group (**Methods**). This analysis

showed increased activity of the Wnt signaling pathway in cells carrying a somatic deletion at 10q24.32 (10% FDR; **Fig. 3e**). We also identified c-Met signaling, which is promoted by the Wnt pathway⁶⁸, to be significantly more active in the SV bearing cells (FDR 10%; second rank after Wnt signaling). In support of this prediction, we performed bulk RNA-seq for 42 CLLs, which notably revealed CLL_24 as an outlier demonstrating the highest Wnt signaling target gene expression amongst all CLLs examined (**Fig. 3f**). Moreover, the availability of bulk RNA-seq data for 178 CLL patient samples from ICGC⁶², allowed us to attempt further validation of our predictions. We indeed observed significant overexpression of *DNM2*, as well as significant upregulation of Wnt and c-Met signalling in CLL samples carrying somatic 10q24.32 deletions (10% FDR; CLLs with the deletion: $N=4$; no 10q24.32 SV: $N=174$; **Fig. 3g-h**, **Fig. S20**), which orthogonally supports the predictions made by scNOVA. Aberrant activation of Wnt signaling is crucial for CLL pathogenesis⁶⁹. To date, few genetic lesions have been linked with aberrant Wnt signalling in CLL⁶⁹, and our findings suggest this pathway is associated with recurrent somatic loss of 10q24.32.

While these results suggest the Wnt pathway is activated in cells containing any deletion spanning the “minimal segment”, we also tested the activity of each independent subclone represented by distinct 10q24 somatic deletions (**Fig. S16**). Given the low CF of these subclones (each $\leq 3.5\%$), we used the alternative PLS-DA mode of scNOVA to infer gene activity for low frequency subclones represented by at least two cells. This clone-by-clone analysis suggested that the Wnt signaling pathway activation was concentrated within just two of the subclones, with subclone ‘C2’ showing the highest pathway activation and subclone ‘C1’ showing no evidence of Wnt signaling activation (**Fig. S17**). Together, these analyses suggest that scNOVA can uncover sub-clonal functional outcomes of driver SVs, and disentangle the relative contribution of low-abundant subclones to aberrant pathway activity in primary patient samples. Studies to date have not yet identified which genes specifically promote aberrant Wnt pathway activity at 10q24.32, a locus comprising several genes that are known to, or have been suspected to, negatively regulate Wnt signaling (**Fig. 3b**, **Fig. S17**, **Supplementary Discussions**). This includes genes directly located in the 10q24.32 minimal segment, such as: *NFKB2* (encoding Nuclear Factor Kappa B Subunit 2), and *FBXW4* (encoding F-box/WD repeat-containing protein 4)⁷⁰, as well as genes very close to the minimal segment, such as: *BTRC* (F-box/WD repeat-containing protein 1A)⁷¹, which resides just 58kb upstream from the minimal region boundary and was found deleted in 9/11 cells in CLL_24. Notably, when analysing published ICGC transcriptomic data⁶², *NFKB2* did not show significant changes in gene expression (FDR-adjusted $P=0.507$; Wald’s test), whereas both *FBXW4* and *BTRC* were clearly down-regulated in CLL samples exhibiting 10q24.32 deletions (FDR-adjusted P -values 0.00478 and 0.000646, respectively); **Fig. S17**). This suggests that *NFKB2* hemizygous loss is unlikely to be responsible for Wnt activation in 10q24.32 deletion bearing cells, whereas *FBXW4* and *BTRC* represent promising targets for future investigation.

Haplotype-specific NO patterns in RUNX1-RUNX1T1 driven acute myeloid leukaemia (AML). Having gained new insight into recurrent SVs in CLL, we next applied scNOVA to a primary AML patient sample (32-year-old male; patient ID=AML_1). We sorted CD34+ primary cells from AML_1 (**Fig. S21**), and produced 42 Strand-seq libraries. SV discovery revealed a 46,XY,t(8;21)(q22;q22) karyotype consistent with clinical diagnostics, with the t(8;21) translocation, detected based on template strand co-segregation²⁸, resulting in the well-known *RUNX1-RUNX1T1*⁷² gene fusion (**Fig. 4a**, **Fig. S22**). We pooled the single cells into phased pseudo-bulk NO tracks to map the breakpoints of this SV to intron 1 of *RUNX1T1* and intron 5 of *RUNX1*, consistent with prior reports⁷³. We did not detect subclonal heterogeneity in AML_1, indicating a stable karyotype, which precluded the use of scNOVA to assign subclones to dysregulated pathways. Instead, we explored genome-wide patterns of gene dysregulation in AML_1 by analysing haplotype differences in NO at gene bodies. Since cancer-specific alterations are often localized to a single homolog¹⁷, we reasoned that haplotype-specific NO analysis could be informative to predict cancer-related gene dysregulation (**Methods**). Using the phased pseudo-bulk NO tracks, scNOVA revealed 11 genes with significant haplotype-specific NO at 10% FDR (**Table S2**). This included the *RUNX1T1* gene body, which was more accessible on the derivative (translocation) haplotype in line with its haplotype-specific activity (**Fig. 4b**), suggesting that haplotype-specific NO reflects the aberrant gene activity at this oncogenic locus⁷³. The additional genes showing haplotype-specific NO included *ARFGEF1* and *NPR2*, which were previously reported to be dysregulated in cells bearing the *RUNX1-RUNX1T1* gene fusion⁷⁴, and CD98 (*SLC3A2*), which promotes AML lethality⁷⁵ and represents a putative therapeutic target (**Fig. 4b**, **Fig. S23**).

These analyses notably suggest the ability of scNOVA to uncover cancer-related changes in gene activity based only on analyzing genome-wide haplotype-specific NO, an approach with potential for discovering cancer drivers and therapy targets in genetically heterogeneous samples.

Next, we considered that fine-grained analysis of haplotype-resolved NO profiles may allow us to dissect the consequences of this balanced translocation on the local *cis*-regulatory landscape. We used the phased pseudo-bulk NO tracks to analyse haplotype-specific NO on either side of the SV breakpoint with scNOVA, by using a sliding 300kb window with a 10kb offset (**Methods**). This analysis revealed widespread haplotype-specific NO around the SV breakpoint: particularly, we observed broadly decreased NO (suggestive of increased chromatin accessibility) on the SV-affected when compared to the unaffected homolog (**Fig. 4c**). At finer-scale, analysis of haplotype-specific NO showed a pronounced decrease in NO in a large distal region 0.8 to 1.1Mb upstream of *RUNX1* ($P < 0.003$; likelihood ratio test, adjusted using permutations; **Fig. 4c**). This region was previously shown to interact physically with the *RUNX1* promoter in normal CD34+ cells⁷⁶. Application of scNOVA revealed two significant CREs in this distal segment showing absence of NO on the derivative chromosome at FDR 10% (Exact test), indicating the CREs are more accessible on the derivative chromosome (**Fig. 4d, Table S5**). The depletion of nucleosomes at these two CREs in physical proximity to the *RUNX1* promoter⁷⁶ suggests that they may foster or support aberrant *RUNX1-RUNX1T1* expression in AML_1. Furthermore, chromosome-wide analyses indicated that the haplotype-imbalanced NO was restricted to the two topologically associating domains (TAD) that were predicted to be fused as a result of the translocation (**Fig. 4e**). These analyses suggest the potential of scNOVA for dissecting changes in local *cis*-regulatory landscapes resulting from somatic driver SVs, and reveal epigenetic remodelling of regulatory regions in association with the t(8;21) translocation in AML_1 likely contributing to aberrant *RUNX1-RUNX1T1* fusion gene expression.

Haplotype-specific functional outcomes of complex DNA rearrangement processes in leukemia

Deconvoluting the outcomes of subclonal chromothripsis with scNOVA. We previously reported a subclonal chromothripsis event with unclear functional outcome in a T-ALL patient-derived xenograft (PDX) sample (TALL-P1)²⁸. While catastrophic mutation processes such as chromothripsis play key roles in cancer development, deciphering their functional effects remains an essentially unsolved challenge^{9,12,77}. This motivated us to use scNOVA to deconvolute the outcomes of this subclonal DNA rearrangement. TALL-P1, in particular, harbors two subclones²⁸: the dominant (CF=70%) subclone lacks complex SVs, whereas the minor subclone (CF=30%) exhibits a chromothripsis event rearranging most of chromosome 6q (depicted in **Fig. 5a**). Analysis using scNOVA identified 12 genes with differential NO between the two subclones (for simplicity, denoted the ‘chromothripsis-associated gene activity signature’ below; 10% FDR; **Fig. 5b; Table S2**). Almost all (10/12 (83%)) of these genes reside on different chromosomes other than chromosome 6, leading us to search for *trans* regulatory effects arising from the chromothripsis event. Closer analysis of the ~90Mb-sized rearrangement showed that 27 TFs reside in the chromothriptic region (**Fig. 5a**). We performed gene-set overrepresentation testing using the target genes of these 27 TFs with scNOVA, which notably revealed only one TF – c-Myb, the product of the *MYB* oncogene – as significantly enriched (FDR-adjusted P -value=0.00015; **Fig. 5c**). In fact, half (6/12) of the genes which scNOVA inferred to be altered in activity represent known c-Myb targets (**Fig. 5b-c; Table S6**). 5 out of these 6 genes were inferred to be upregulated in the chromothriptic subclone, which included: *RHOH* - a Rho GTPase frequently overexpressed in T-ALL⁷⁸, *NOTCH1* - a TF and prototypical oncogene frequently exhibiting activating point mutations in T-ALL⁷⁹, and *SLC9A7* (*NHE7*) - a membrane protein previously shown to enhance breast tumor formation⁸⁰. The only gene inferred to be downregulated was *PRKCB* - a PKC kinase shown to display tumour suppressive functions in a colon cancer model⁸¹. Taken together, scNOVA nominates *MYB* as a candidate driver gene dysregulated as a consequence of chromothripsis, by revealing the aberrant activity of several *MYB* target genes.

Orthogonal support from bulk RNA-seq. To corroborate these predictions, we first performed bulk RNA-seq in a panel of 13 T-ALL samples, including TALL-P1. Leveraging the whole-chromosome haplotypes from Strand-seq, we performed allele-specific expression analysis resolved by haplotype in TALL-P1, which revealed aberrant expression of *MYB* from the SV-affected chromosome ($P=0.0317$; likelihood ratio test, 1.4-fold increase in homolog-resolved gene expression; **Fig. S25**) – consistent with *MYB* dysregulation emerging as a direct

consequence of chromothripsis. We next compared gene expression measurements for known c-Myb targets (**Table S7**) among all 13 T-ALL samples, which showed that TALL-P1 exhibited the highest expression of c-Myb targets amongst all samples tested, including high outlier expression of *RHOH* (**Fig. 5d**, **Fig. S26**) – thus further corroborating the inferences made with scNOVA.

Verification and refinement of the chromothripsis-associated gene activity signature via scRNA-seq. Second, to provide a more detailed analysis of the chromothripsis subclone we generated an orthogonal scRNA-seq (10X Genomics) dataset comprising 5,504 TALL-P1 cells (**Fig. 5e**). As seen earlier, when applying several current methods for inferring SCNAs from scRNA-seq data^{50–52}, we were unable to discover any somatic SVs on chromosome 6 based on these single cell expression data (**Table S4**) – in spite of the fact that the chromothriptic region collectively comprises 227 expressed genes. However, when using the high-resolution breakpoints identified by our framework as an input to CONICSmatrix, we successfully produced targeted “genotype” calls in a subset of the single cell data. CONICSmatrix confidently genotyped 15% of the scRNA-seq dataset for which 729 cells were predicted to harbor the chromothripsis rearrangement, and 109 cells were called “normal” [disomic] across the entire chromosome 6 (for the remainder of cells no confident assignment could be made; **Fig. 5f**). Those single cells inferred to contain the chromothripsis event notably showed significant enrichment in two clusters, denoted cluster 3 and cluster 7, which emerged from unsupervised clustering analysis (adjusted $P=3.43\text{e-}5$ and $1.15\text{e-}3$ respectively; FDR-adjusted Fisher’s exact test; **Fig. 5h**) – whereas confident normal cells were enriched in clusters 4 and 6 (**Fig. S28**). We next tested whether the chromothripsis-associated gene activity signature inferred by scNOVA could be used to independently identify cells harbouring the sub-clonal SV. Using UCell⁸², we found both cluster 3 and cluster 7 were significantly enriched for cells comprising high expression scores for the 12 genes contained in this gene activity signature (**Fig. 5h, g**; $P=3.39\text{e-}38$ and $P=2.15\text{e-}4$, respectively; FDR-adjusted Fisher’s exact test). These complementary analyses therefore suggested that the chromothriptic clone is enriched in scRNA-seq clusters 3 and 7. Notably, differentially expressed genes of both clusters 3 and 7 were significantly enriched with c-Myb target genes (adjusted $P=4.25\text{e-}26$, and $P=1.88\text{e-}26$, respectively; **Fig. 5i**, **Table S10**), which orthogonally validates the aberrant c-Myb activity initially predicted by scNOVA. In addition to c-Myb, cluster 3 was enriched for *EKLF* and *MYC* targets, which act downstream of c-Myb^{83,84}. Finally, we performed trajectory analysis on the scRNA-seq data⁸⁵, which suggested a more primitive state in clusters 3 and 7 compared to other clusters (**Fig. S29**). This is perhaps explained by a differentiation block at the progenitor stage, which has been previously associated with c-Myb hyperactivity in leukemia⁸⁶. The agreement between genotype (a somatic chromothripsis event) and molecular phenotype (gene activity dysregulation of c-Myb targets) in these orthogonal data sets directly supports the ability of scNOVA to infer functional consequences of complex SVs in the same leukemic single cells. Collectively, our results indicate that allele-specific c-Myb dysregulation resulted from a one-off catastrophic rearrangement event in TALL-P1, leading to aberrant expression of c-Myb targets and a more primitive cell state. To our knowledge, this is the first example of how single-cell multiomics can be used to decipher the functional effects of chromothripsis – emphasising the potential of scNOVA to dissect the functional consequences of catastrophic mutational processes in other cancers.

Discussion

A novel single cell multiomic framework to functionally characterise somatic SVs. Functional characterization of somatic SVs is of critical importance for the interpretation of cancer genomes because SVs outnumber somatic point mutations as drivers^{1,2}. The scNOVA single-cell multiomic framework directly links somatic SVs to their functional consequences by integrating genetic and molecular readouts from the same cell. Using scNOVA we can now: dissect intra-sample genetic heterogeneity at single-cell resolution, measure the haplotype-specific impact of SVs, explore global gene dysregulation in SV-containing cells, discriminate genetically-distinct subclones, and identify unique and shared functional consequences of heterogeneous SVs affecting the same genomic interval. Strand-seq accesses the full spectrum of SV classes $\geq 200\text{kb}$ in size²⁸, which scNOVA now couples to NO measurements to enable their simultaneous functional characterization within the same single-cell sequencing experiment. According to the PCAWG cancer genomic resource, 83% of cancer SV drivers fall within the SV spectrum² accessible to Strand-seq. This means that scNOVA can interrogate the gene and pathway activity changes resulting from a considerably wider spectrum of SVs compared to prior single-cell multiomics methods, which are largely restricted to arm-level or very large interstitial SCNAs $>10\text{Mb}$ in size (see also **Supplementary**

Discussion). Despite employing several state-of-the-art methods for inferring SCNA in paired scRNAseq datasets, we were unable to discover the somatic SVs predicted with Strand-seq data when using scRNAseq, unless we first defined the high-resolution breakpoints for targeted SCNA detection. This is consistent with the resolution of our framework being significantly higher compared to the discovery of SCNA based on scRNA-seq alone. On the other hand, using this targeted genotyping approach, we found that Strand-seq and scRNA-seq can be successfully combined to more completely deconvolute patterns of subclonality and intra-tumor heterogeneity. This study altogether analysed 2,178 single-cell genomes and 12,911 single cell transcriptomes (**Table S1, Table S4**), and using these we showed that scNOVA infers changes in gene activity that are generally well-recapitulated by expression data. Our study linked SVs representing copy-imbalanced, copy-neutral and complex rearrangement classes with a functional outcome. Since copy-neutral SVs are captured by our framework, largely euploid (copy-number stable) malignancies previously considered inaccessible²¹ can now be studied by single-cell multinomics using our framework.

Linking intra-sample genetic complexity to expression dysregulation. Due to the widened spectrum of SVs accessible to our framework, scNOVA enables a more comprehensive dissection of subclonal genetic complexity. We report a >7-fold increase in somatic SVs compared with prior studies in LCLs, and implicate novel somatic SVs in LCLs with gene activity changes. For instance, we found a somatic deletion at 19q13.12 in the widely-used NA12878 cell line, and linked this subclonal SV to *ERCC6* over-expression and dysregulation of cancer-related pathways, such as MAPK signaling and c-Myc/Max target gene activation (**Fig. S13**). We also observed unusual karyotypic diversity in a primary CLL sample, which harbored distinct deletions affecting the 10q24.32 locus. By measuring the subclonal consequences of distinct SV events in the same patient, scNOVA linked this previously described putative driver to aberrant activation of the Wnt signaling pathway. Whether the *FRA10B* fragile site is involved in the formation of these somatic deletions remains to be seen, and will necessitate analyses of larger cohorts. However, we note that CLL_24 exhibits a SNP (rs118137427; 3.7% allele frequency in Europeans) which tags expanded repeat sequences at *FRA10B* that were associated with the acquisition of terminal 10q mosaic deletions in normal blood⁸⁷. Based on the PCAWG resource comprising 94 CLLs², rs118137427 is seen in 2/4 (50%) CLLs with 10q24.32 deletions, but in only 6/90 (6.7%) CLLs with an intact 10q ($P=0.035$; Fisher's exact test), suggesting a possible link between germline genetic variants at *FRA10B* and somatic SVs in CLL that future studies may explore.

Functional dissection of complex karyotypes. SVs functionally characterized by scNOVA include those arising from catastrophic rearrangement processes. While complex SV classes have been associated with aggressive tumor phenotypes^{2,77}, their functional impact has remained largely unclear, with functional interpretation typically limited to gene loci that are highly amplified in copy-number^{2,23,77}. We showcase the high resolution of scNOVA by functionally dissecting a BFB-mediated complex karyotype in NA20509, resulting in monoallelic *MAP2K3* expression and c-Myc/Max target dysregulation. In addition we dissect a subclonal chromothripsis event in a T-ALL-derived sample, directly linking chromothripsis to c-Myb target deregulation by single-cell multinomics, to report a previously undescribed mechanism for *MYB* oncogene activation in T-ALL. Pursuing paired scRNA-seq for the same patient sample enabled us to locate the chromothriptic clone in the clustered expression data, which in turn allowed us to comprehensively characterize the differential gene activity changes and primitive cell state of the somatic subclone. The agreement we found between these orthogonal datasets verified the predictions made by scNOVA, illustrating how we can now comprehensively infer the functional consequences of complex subclonal SVs in the same leukemic single cells. These results highlight significant potential of scNOVA as a framework to study the impact and dynamics of complex rearrangements in cancer.

Technical considerations and remaining limitations. scNOVA considers three separate genomic readouts: somatic SVs, gene activity, and CRE accessibility around the SV breakpoints – all obtained from only one single-cell assay: Strand-seq. Since our workflow does not require coupling distinct experimental modalities in each individual cell, well-known challenges of single-cell multinomics methods²¹ such as increased costs (e.g. from pursuing paired RNA and DNA sequencing from the same cells) and data sparseness (e.g. loss of data from any one of the paired experimental modalities⁸⁸) are overcome. One could consider also integrating ATAC-seq into the Strand-seq assay, potentially enabling enhanced analysis of chromatin accessibility; however, this would come

at the price of significantly lower resolution of SV calls, given the less uniform coverage of transposase- compared to MNase-mediated cuts⁸⁹. The relatively high coverage achieved by Strand-seq enables the analysis of haplotype-specific NO along whole chromosome homologs (**Fig. S30**), allowing dissection of SV functional outcomes *in cis*. This provides certain advantages over classical allele-specific analyses, which are restricted to phased sequences containing heterozygous SNPs typically reflecting up to 15% of the genome¹⁷.

Nevertheless, key challenges in single-cell sequencing remain, and the full spectrum of somatic mutations arising in an individual cell is likely to remain inaccessible to studies in the foreseeable future. Because scNOVA harnesses the increasingly used Strand-seq technique^{41,90,91}, it captures the whole spectrum of SVs ≥ 200 kb, but misses smaller ones such as mobile element insertions (albeit, this SV class more rarely acts as cancer driver²). While revealing differentially active genes, scNOVA does not span the dynamic expression range accessible to RNA-seq nor provides quantitative gene expression measurements of individual genes. Finally, Strand-seq requires dividing cells for BrdU labeling (**Fig. 1a**), and is hence not applicable for non-dividing cells and formalin-fixed samples. However, it can be utilized for dividing cells in cell lines, PDX models, organoids, primary fresh frozen progenitor cells, cells in regenerating tissues, leukaemia cells, and cancer samples amenable to culture. As customary when developing new methods, we used cell lines for benchmarking followed by proof-of-principle application in patient-derived samples. Generalisation of these studies in larger patient cohorts will in the future allow elucidating relevant roles of subclonal SVs in leukaemogenesis.

Potential future applications: non-genetic determinants of cancer, pre-cancer studies, translational medicine. Technical challenges and limitations notwithstanding, we foresee a wide variety of potential future applications using scNOVA. Our framework offers potential for studies on the determinants and consequences of genomic instability in cancer, and may promote research into the interplay of genetic and non-genetic cancer determinants, including epigenetic plasticity implicated in metastatic potential²¹. It likewise could be used to advance surveys of precancerous lesions, in which roles of SV are understudied^{21,92}. Robust determination of SVs in single cells is a known challenge⁹², and scNOVA can increase confidence in single-cell SV discovery by allowing to identify haplotype-resolved SVs and their functional effects in the same cell. This is exemplified by the *RUNX1-RUNX1T1* oncogenic fusion in AML, which in addition to yielding a rearranged DNA sequence results in a discernible pattern of haplotype-specific NO at CREs around the rearrangement breakpoint. In addition, scNOVA might offer future value in precision oncology by exposing subclonal driver alterations along with their targetable functional outcomes, to potentially allow therapeutic targeting of cancer subclones. Furthermore, SVs can accidentally arise in key model cell lines, and scNOVA's features are ideally suited to functionally characterise unwanted heterogeneity in such samples. As a proof-of-principle, we demonstrated dissection of the outcomes of undesired SVs in widely used LCLs, which includes NA12878, key reference cell line for 1KGP, ENCODE, and NIST^{34,43,44}. Indeed, the extent of somatic SVs that our framework uncovered in LCLs indicates that human model cell lines, used for fundamental discoveries in translational medicine and tumour biology, may show more widespread and functionally impactful genetic heterogeneity than currently anticipated. Unwanted somatic SVs also arise as a by-product of CRISPR-Cas9 genome editing, which generates micronuclei and chromosome bridges in human primary cells, structures that initiate the formation of chromothripsis⁹³. scNOVA could promote the safety of therapeutically relevant genome editing in the future, by enabling the simultaneous detection and functional characterization of such potentially pathogenic editing outcomes in single cells.

In summary, scNOVA moves directly from SV landscapes to their functional consequences in heterogeneous cell populations. By making a broad spectrum of somatic SVs accessible for functional characterisation genome-wide, this single-cell multiomic framework serves as the foundation for deciphering the impact of somatic rearrangement processes in cancer.

Acknowledgements

We thank Arnaud Krebs, Judith Zaugg, Karsten Rippe and Isidro Cortés-Ciriano for providing thoughtful feedback on the development of scNOVA. We also thank Malte Paulsen (Flow Cytometry Core Facility) for assistance in cell sorting, Benjamin Raeder for assisting in Strand-seq library preparation, and the EMBL Genomics Core Facility for assisting in single-cell automation (Jürgen Zimmermann and Vladimir Benes) and scRNA-seq library preparation (Laura Villacorta). Finally, we thank Wolfram Höps for assistance with single-cell analysis, as well as Margit Happich and Paulina Richter-Pechanska for assistance with RNA-seq analysis.

Funding

Principal funding came from the European Research Council (ERC Consolidator grant no. 773026, to J.O.K.). Funding also came from the an ERC Starting Grant (grant number 336045) to J.O.K., the National Institutes of Health (grant no. 2U24HG007497-05) to J.O.K. and T.M., the Baden-Württemberg Stiftung (for supporting the projects “Epigenetics in T-ALL” and “SV_Surveillance”) to J.O.K. and A.E.K., and the German Federal Ministry of Education and Research (grant no. 031A537B; de.NBI project) to J.O.K. H.J. and A.D.S. acknowledge fellowships through the Alexander von Humboldt Foundation. We thank the Human Genome Structural Variation Consortium for providing early access to deep bulk RNA-seq data from several LCLs (generated using funds provided by NHGRI Grant 2U24HG007497-05). D.N. is an endowed Professor of the German José-Carreras-Foundation (DJCLSH03/01). J.C.J was funded by a Gerok position of the “Deutsche Forschungsgemeinschaft” (DFG) (NO 817/5-2, FOR2033, NICHEM).

Author contributions

Study design (including conceptualisation of haplotype-specific NO analysis, cell-type classification, and altered gene activity using Strand-seq data): H.J., K.G., A.D.S., J.O.K.; development of scNOVA computational method: H.J., K.G., A.D.S., J.O.K.; single-cell SV discovery: H.J., K.G., A.D.S., J.O.K.; LCL Strand-seq experiments: A.D.S., P.H.; CLL Strand-seq experiments: K.G., P.B., S.D.; AML Strand-seq experiments: K.G., J.-C.J., D.N.; WGS-based somatic SV discovery and verification: T.R.; whole chromosome haplotype-phasing: H.J., D.P., T.M.; LCL RNA-seq analysis: H.J.; LCL scRNA-seq analysis: H.J.; CLL RNA-seq analysis: H.J., S.H., P.B., S.D.; T-ALL RNA-seq analysis: H.J., B.E.-U., A.E.K.; PCAWG SV driver spectrum analysis: R.S., J.O.K.; Joint first authors: H.J., K.G. Joint senior and corresponding authors: A.D.S., J.O.K. The manuscript was written by H.J., K.G., A.D.S. and J.O.K., with additional contributions from all authors.

Competing interests

The following authors have previously disclosed a patent application (no. EP19169090) that is relevant to this manuscript: A.D.S., J.O.K., T.M., and D.P.

Data and materials availability

The code of scNOVA is available open source at <https://github.com/jeongdo801/scNOVA>, with no restrictions on reuse. LCL data are available under the following accessions: Strand-seq (PRJEB39750); RNA-seq (ERP123231); WGS (PRJEB37677). Leukemia patient data were deposited in the European Genome-phenome Archive (EGA), under the following accession numbers: T-ALL Strand-seq and scRNA-seq (EGAS00001003365), CLL Strand-seq (EGAS00001004925), AML Strand-seq (EGAS00001004903), T-ALL bulk RNA-seq (EGAS00001003248), CLL bulk RNA-seq (accession in progress).

Methods

Ethics statement

The protocols used in this study received approval from the relevant institutional review boards and local ethics committees. Written informed consent was obtained from patients, and all experiments were consistent with current bioethical policies. T-ALL experiments were approved by the ethics commission of the Kanton Zurich (approval number 2014-0383).

Strand-seq in primary leukemia cells

Peripheral blood mononuclear cells of a previously untreated female CLL patient (routine diagnostics: *IGHV* unmutated, no *TP53* mutation, no detected alteration in 6q21, 8q24, 11q22.3, 12q13, 13q14 und 17p13) were isolated after obtaining informed consent. Cells were isolated and cultured using previously established protocols⁹⁴. CLL cells were cultured at 1×10^6 cells/ml in Roswell Park Memorial Institute (RPMI) medium (Gibco by Life technologies), supplemented with 10 % human serum (PAN BIOTECH), 1 % Pen/Strep (GIBCO by Life Technologies) and 1 % Glutamine (GIBCO by Life Technologies). Cells were stimulated with 1 μ g/ml Resiquimod (Enzo) and 50 ng/ml IL-2 (Sigma). BrdU (40 μ M; Sigma) was incorporated for 90 h and 120 h, respectively, to perform non-template strand labeling. Single nuclei from each timepoint were sorted into 96-well plates using a BD FACSMelody cell sorter, followed by Strand-seq library preparation (described below).

In the case of the AML sample, frozen primary mononuclear cells from a bone marrow aspirate were thawed and stained with CD34-APC (clone 581; Biolegend), CD38-PeCy7 (clone HB7; eBioscience), CD45Ra-FITC (clone HI100; eBioscience), CD90-PE (clone 5E10; eBioscience), and LIVE/DEAD™ Fixable Near-IR Dead Cell Stain (ThermoFisher). Single, viable, CD34+ cells (**Fig. S21**) were sorted using a BD FACSARIA™ Fusion Cell Sorter into ice-cold Serum-Free Expansion Medium (SFEM) supplemented with 100 ng/ml SCF and Flt3 (Stem Cell Technologies), 20 ng/ml IL-3, IL-6, G-CSF and TPO (Stem Cell Technologies). Cells were plated in Corning Costar Ultra-Low Attachment 96-well flat-bottom plates (Sigma) at 1×10^5 cells/ml in warm medium as above. 24 h after culture, 40 μ M BrdU was added. Nuclei were isolated after 43 h total culture time, and BrdU-incorporating nuclei sorted into 96-well plates followed by Strand-seq library preparation.

Strand-seq libraries were prepared using a Biomek FXP liquid handling robotic system, as described previously^{24,95}. Libraries were sequenced on an Illumina NextSeq500 sequencing platform (MID-mode, 75 bp paired-end sequencing protocol) to a median depth of 551,831 (CLL) and 371,159 (AML) mapped non-duplicate fragments per cell, respectively. Strand-seq data generated with this protocol²⁴, involving MNase digestion, largely comprise mononucleosome-sized (140-180bp) fragments (**Table S1**).

Strand-seq data preprocessing and library selection in leukemia-derived single cells

Reads from Strand-seq (fastq) libraries were aligned to the hg38 assembly using bwa⁹⁶, as previously described²⁸. Sequence reads with low quality (MAPQ<10), supplementary reads, and duplicated reads were removed. Single cell library selection was performed as described previously²⁸. The single-cell footprints of different SV classes were discovered using the principle of single cell tri-channel processing (scTRIP) of Strand-seq data, using the MosaiCatcher computational pipeline with default settings²⁸, as described in the scNOVA workflow further below. In the AML sample, a reciprocal translocation involving chromosomes 8 and 21 resulting in a *RUNX1-RUNX1T1* fusion gene was inferred based on template strand co-segregation²⁸, using a MosaiCatcher FDR-adjusted *P*-value of 0.000026 (event seen in 37/37 cells; 5 cells with sister chromatid exchange (SCEs) affecting the respective translocation partners were excluded from the FDR-adjusted *P*-value computation using the MosaiCatcher pipeline²⁸). As we identified extensive subclonal heterogeneity in the CLL sample, we used the ‘lenient SV calling parameterization’ available using the MosaiCatcher pipeline²⁸ to allow for sensitive detection of SVs at CFs from 1 to 5%, including in individual cells.

scNOVA workflow: coupling NO measurements and SV discovery in the same cell

We developed scNOVA as a computational tool for coupling discovered somatic SVs with analyses of NO profiles – in the same cell. The scNOVA workflow covers a set of different operations from single-cell SV discovery (using the previously described scTRIP method²⁸) to NO profiling at CREs, and gene as well as pathway dysregulation inference based on NO at gene bodies, and can be used in a haplotype-aware or -unaware manner. To maximize reusability, interoperability and reproducibility we combined all of scNOVA’s modules into a coherent workflow using snakemake. Alternatively these modules can be executed individually.

Nucleosome occupancy (NO): data analysis and operational definition utilised

We operationally defined nucleosome occupancy (NO) closely following definitions from a prior study²⁹: NO maps were calculated by counting how many reads from the Strand-seq libraries (which typically comprise mononucleosomal fragments ~140-180 base pairs in size; see **Table S1**, **Fig. S2**) covered a given base pair based on aligning reads to the GRCh38 (hg38) genome assembly with BWA⁹⁶. Genomic regions with unusual (such as artificially high) coverage were considered artifacts, and were automatically excluded (“blacklisted”) by our

Strand-seq analysis workflow as previously described²⁸. No further peak calling or smoothing was conducted, and no assumptions on the length of the nucleosomal DNA were made to derive NO maps, as nucleosome boundaries were determined on both sides of the nucleosome by paired-end sequencing²⁹. For the calculation of NO around bound CTCF binding sites (downloaded from ENCODE³⁴), the averaged profile was scaled²⁹ to yield an NO equal to 1 at position -2000bp from the center of the bound CTCF site.

Cell type classification

To initially assess the utility of Strand-seq derived NO patterns for cell type classification, we generated feature sets from the NO at the body of genes (defined as the region from the TSS to the transcription termination site (TTS), which includes exons and introns) at the single-cell level. NO in gene-body regions was normalized by segmental copy number status, and by library size to obtain reads per million (RPM), which we transformed into log₂ scale. This feature set was used for the unsupervised dimension reduction plot (**Fig. S7**) and for training of a supervised classification model based on partial least squares discriminant analysis (PLS-DA)⁹⁷. To train the supervised cell type classifier based on gene-body NO, we used 179 single-cell Strand-seq libraries generated from two diploid LCLs (50 cells from HG02018, 50 cells from NA19036), as well as from a replicate of the near-diploid RPE-1 cell line (79 cells; ‘replicate 1’²⁸). 19,629 ENSEMBL genes with at least one read detected at the respective gene-bodies were considered as initial input feature sets. An X matrix [179 cells-by-features] and a Y matrix [179 cells-by-two cell type] were prepared for PLS-DA, in order to find latent variables which can explain the variability in Y using linear combinations of features in the X matrix. Using three latent variables which explain 98.48% of the variance of the Y variable, variable importance of projection (VIP) for each feature was calculated. Highly informative features (VIP>90% of null distribution) were selected to build the final classifier. Classification performance of the final classifier was evaluated by leave-one-out cross validation using the 179 cells, which yielded 100% accuracy of classification (are under the curve (AUC)=1) with six latent variables. Finally, we applied this model to an independent validation using a different LCL (46 cells from HG01573) and the same RPE-1 epithelial cell line, albeit using a different replicate (77 cells; ‘replicate 2’), verifying 100% classification accuracy with independently generated data (AUC=1). To generate the UMAP shown in **Fig. S7**, 302 cells including those from the training set (179 cells) and the independent validation set (123 cells) were projected onto the final classification model. The resulting prediction score of six latent variables for each cell was used to perform UMAP⁹⁸ for dimensionality reduction.

Haplotype-phasing of single-cell NO tracks. As previously described, Strand-seq directly resolves its underlying sequence reads onto haplotypes ranging from telomere to telomere³² (chromosome-length haplotyping). scNOVA phases NO profiles onto a chromosomal homolog using the StrandPhaseR algorithm³², which is employed wherever the template strand segregation pattern of a chromosome enables unambiguous haplotype-phasing – that is, for Watson/Crick (WC) or Crick/Watson (CW) template state configurations in Strand-seq libraries^{32,95}. Haplotype-specific analyses pursued by scNOVA employ phased reads (normalized by locus copy-number), whereas the inference of gene activity changes uses both phased reads (from chromosomes with a WC or CW configuration) and unphased reads (from chromosomes with a CC or WW configuration^{32,95}).

Inference of haplotype-specific NO at cis-regulatory elements (CREs). To allow inference of haplotype-specific NO at CREs, scNOVA requires the location of CREs as another input in bed format (REs_hg38.bed). CREs can be defined using DNase I hypersensitive sites (DHSs), or alternatively based on accessible chromatin segments obtained using ATAC-seq⁸⁹. As a default functionality, scNOVA considers DHSs provided from 127 epigenomes³⁵ from the Roadmap Epigenomics Consortium and ENCODE (covering a variety of human tissue types). scNOVA also provides the option to use CREs from user-defined DNA accessibility profiling experiments (provided in ‘bed’ format). After aggregating haplotype-phased single-cell NO tracks into pseudo-bulk tracks, NO is measured based on assessing the read depth at defined CREs, using haplotype-resolved reads. Haplotype-specific NO is measured using the Exact Test followed by controlling the False Discovery Rate⁹⁹ (FDR), using EdgeR software¹⁰⁰. CREs are assigned to their likely target genes using a nearest gene approach using the prioritisation rules described in³⁸.

Inference of genome-wide changes in gene activity. This haplotype-unaware module of scNOVA considers all reads – whether they are phased or not – to infer gene activity alterations via analysis of differential patterns of NO along gene bodies. scNOVA obtains gene loci from ENSEMBL (GRCh38.81), converted into bed format (Genebody_hg38.81.bed). Strand-seq reads falling within the start and end position of genes (Genebody_hg38.81.bed) were identified with the Deeptool multiBamSummary function¹⁰¹, using the following parameters:

```
multiBamSummary BED-file --BED Genebody_hg38.81.bed --bamfiles Input.bam --extendReads --outRawCounts output.tab -out output.npz
```

scNOVA's gene dysregulation inference module contains two steps. *Step 1* filters out genes unlikely to be expressed ('not expressed', NEs). *Step 2* infers dysregulated (*i.e.* differentially expressed) genes between subclones using a generalized linear model.

In *Step 1*, scNOVA first aims to infer gene expression 'On' and 'Off' states¹⁰² from NO, by analysing NO as well as gene context-specific sequence features along gene bodies using deep convolutional neural networks¹⁰³ (CNNs).

Both phased and unphased single-cell reads were used to generate NO profiles. Feature sets were incorporated into one-dimensional CNNs. To define the feature sets for each gene, we considered genomic regions spanning the body of genes, which we – for the purpose of the CNN – expanded from 5kb upstream of the TSS until 5kb downstream of the TTS, to include 5kb of flanking non-transcribed sequences on each flank which appeared informative as well (**Fig. 1f**). Each gene was divided into 150 bins, whereby we considered genomic annotations of the start and end coordinates of genes provided via ENSEMBL's GTF file, as follows: 50 bins for the region -5kb to the TSS, 50 bins for the gene-body, and 50 bins for the region from the TTS to +5kb. Five layers of feature sets were derived for those 150 bins: NO, single cell variance of NO, GC content, CpG content, and replication timing, which we included in the CNNs to assist bin stratification. To compute NO for *Step 1*, the read depth within each of the 150 bins was first normalized by bin length using smooth spline fitting in R, and then normalized by library size to obtain read per million (RPM) measurements, which subsequently were scaled by the locus copy-number status. To compute the single cell variance of NO, coefficients of variation (CV = standard deviation / mean) for the single-cell read depth were calculated for each bin. Systematic effects of mean on the CV were regressed out using smooth spline fitting. GC and CpG content were computed based on the nucleotide content of each bin, using the Homer annotate peak tool¹⁰⁴. For replication timing, we used a pre-processed signal track (hg19) from the UCSC Genome Browser database¹⁰⁵ (UW Repli-seq track), which we mapped to the hg38 genome using the UCSC LiftOver tool. scNOVA can also consider CNNs for inferring expression in a single cell, which use four rather than five layers of feature sets (excluding single-cell variance of NO, which cannot be computed for a single cell).

To define ground-truth labels of not expressed genes (NEs) and expressed genes (EGs), we used bulk RNA-seq data from three RPE cell lines (RPE-1, BM510, and C7)²⁸. Reads were aligned onto hg38 with STAR aligner (v2.5.3)¹⁰⁶, using gene annotations from ENSEMBL GTF (GRCh38.81). FPKM values were obtained with Alfred¹⁰⁷; genes with FPKM>1 were labeled as EGs, and all remaining as NEs. We used the following numbers of EGs and NEs for training: RPE-1: 10413 EGs, 9131 NEs; BM510: 10339 EGs, 9205 NEs; C7: 10486 EGs, 9058 NEs. We used the hyperopt package¹⁰⁸ to search for optimal hyperparameters for the CNNs (**Fig. S8**).

In leave-one-chromosome-out cross-validation¹⁰³ experiments (where we trained a model leaving out a certain chromosome, and then applied the model to the chromosome previously left out), the CNNs outperformed random forest and SVM based models with the same set of features (**Fig. S9**). To assess model performance for different number of aggregated cells (clones of different sizes), we pooled Strand-seq data to generate randomized pseudo-bulk datasets for 80, 40, 20, 5, and 1 cell (s), respectively, and evaluated CNN performance using leave-one-chromosome out cross-validation. Trained models for each chromosome, and for different clone set sizes, are made available along with the code of scNOVA to facilitate application to new data sets. By default, scNOVA operates with the model trained with a pseudo-bulk of 80 cells, to estimate the probability of each gene to represent an NE in each clone. Genes likely to be unexpressed (NE status probability ≥ 0.9) across clones are filtered out in *Step 1*, and all remaining genes used in *Step 2*.

In *Step 2*, scNOVA by default employs negative binomial generalized linear models, available in the DESeq2 algorithm¹⁰⁹, to infer genes with differential activity between individual cells or clones. As an input, scNOVA computes single-cell count tables of gene-body NO. When running this step with subclones, all

individual cells of the subclone are considered ‘replicates’ in DESeq2 terminology¹⁰⁹. Subclones (or cells) are compared in a pairwise manner using a two-sided Wald test to infer genome-wide alterations in gene activity. Based on this, we defined the differential gene activity score as the sign of the fold change in NO at gene bodies, multiplied by $-\log_{10}$ p-values. Genes with significantly altered activity were identified using a 10% FDR threshold. Additionally, to facilitate the analysis of small CF subclones, scNOVA provides an alternative mode which employs partial least squares discriminant analysis (PLS-DA)⁹⁷ to identify discriminatory feature sets as gene sets showing altered activity. To do this, scNOVA builds a PLS-DA⁹⁷ discriminant model to classify cells in a given subclone 1 and subclone 2 based on single-cell count tables of gene-body NO as feature sets. This model provides a variable importance of projection (VIP) and significance compared to a null distribution in the form of a *P*-value for each gene analyzed. Similar to the default setting, genes with altered activity were identified using a 10% FDR cutoff when using PLS-DA for inferring changes in gene activity between subclones. Benchmarking both modes (see **Fig. S11**) suggested that whereas both DESeq2 and PLS-DA offer acceptable performance, the alternative mode (PLS-DA) outperforms the default setting when the subclonal CF is below 10%, whereas the default mode (DESeq2) generated superior results for CF values of 10% or greater.

Molecular phenotype analysis in gene-sets. This module of scNOVA uses defined gene-sets, obtained from public resources, to identify overrepresented sets of functionally related genes changing in activity between subclones (or individual cells). Two types of analyses are enabled by this module: (1) gene-set overrepresentation analysis, which, for example, can be used to investigate the enrichment of targets of a major transcription factor (TF) among genes showing a change in activity according to gene-body analysis of NO; (2) joint modeling of NO across predefined gene-sets, using pathway definitions from MSigDB⁶⁷.

In the case of gene-set overrepresentation analysis, we collected TF target genes from database entries (EnrichR⁵⁴) as well as by reviewing the literature. When reviewing the literature, we created curated lists of target genes for TFs based on published genome-wide studies using the following strict criteria: (i) target genes show evidence of binding of the TF of interest by ChIP-seq; (ii) the same genes must additionally show differential expression when the TF of interest is experimentally silenced (our curated target gene lists are available in **Table S7**). For each TF, the significance of overlap between its target gene set and genes exhibiting differential NO was computed using hypergeometric tests, followed by controlling the FDR at 10%.

To jointly model differential NO across all genes of predefined pathways, scNOVA first generates a single-cell gene-body NO table using Strand-seq read count data, with these read counts then being normalized using the median-of-ratios method from DESeq2¹⁰⁹. For each member in the biological pathway gene sets from MSigDB⁶⁷, scNOVA then computes mean normalized NO values, in each single-cell, as a proxy for pathway-level NO. Lowly variable genes (standard deviation <80%) are removed. Pathway-level NO is compared between cells with and without SVs using linear mixed model fitting followed by likelihood ratio testing, and controlling the FDR at 10%. For linear mixed model fitting, SV status is defined as a fixed effect and different Strand-seq library batches are defined as random effects, by scNOVA.

Inference of haplotype-specific NO at the body of genes. To measure haplotype-specific NO at gene bodies, scNOVA measures read depth along gene bodies using haplotype-phased single-cell NO tracks. For each gene, gene-body NO measurements from both haplotypes are converted into $\log_2$ -scale and compared using a generalized linear model likelihood ratio test. To infer haplotype-specific gene deregulation in an AML_1 based on NO, we first filtered out genes inferred to be unexpressed (NE status probability ≥ 0.9) using scNOVA’s CNN. For the remaining genes we computed gene-body NO resolved by haplotype. For *RUNX1* and *RUNX1T1*, we computed haplotype-aware NO for the partial gene-body regions participating in the gene fusion (**Fig. S23**). For each gene, single-cell gene-body NO from two haplotypes was converted into $\log_2$ -scale and compared using a generalized linear model likelihood ratio test, controlled using an FDR of 10%.

Haplotype-resolved SV discovery in single cells. The scNOVA computational framework utilizes the previously described scTRIP method for haplotype-aware SV discovery of the full spectrum of somatic SVs ≥ 200 kb in size in Strand-seq data, by executing the MosaiCatcher computational pipeline²⁸. In brief, this pipeline integrates three ‘channels’ – template strand, read depth and haplotype-phase – to discover deletions, duplications, balanced inversions, inverted duplications, balanced translocations, unbalanced translocations and diverse classes of

complex SV including BFBs and chromothripsis events in single cells, and it maps these SVs to a defined chromosomal homolog. All single cells are subjected to SV discovery, regardless of chromosomal template strand configuration²⁸ (such as Watson/Crick (WC), Crick/Crick (CC), or Watson/Watson (WW)), and joint modeling of the data is pursued which increases the detection sensitivity for SVs present in more than one single cell²⁸. By default, scNOVA employs the ‘strict’ scTRIP SV caller, which has been optimized for detecting SVs with CF $\geq$ 5%²⁸. SV discovery can be bypassed in the scNOVA framework, to focus downstream functional investigation to user-defined somatic SVs.

Single-cell RNA sequencing and data processing. Primary human T-ALL cells were recovered from cryopreserved bone marrow aspirates of patients enrolled in the ALL-BFM 2009 study. Patient-derived xenografts (PDX) were generated as previously described by intrafemoral injection of 1 Million viable primary ALL cells in NSG mice¹¹⁰. PDX-derived (P1)²⁸ cells were frozen until processing. For scRNA-seq library preparation, cryopreserved cells were thawed rapidly at 37 °C and resuspended in 10 ml warm Roswell Park Memorial Institute (RPMI) medium with 100 µg/ml Dnase I. Cells were centrifuged for 5 mins at 300 g, and resuspended in ice-cold phosphate buffered saline (PBS) with 2% foetal bovine serum (FBS) and 5mM EDTA. Cells were stained on ice with anti-murine-CD45-PE (mCD45)(clone 30-F11; BioLegend; 1:20) in the dark for 30 mins. 1:100 DAPI was added and incubated in the dark for 5 mins before sorting. Triple negative cells (DAPI-mCD45-GFP-) were sorted (**Fig. S27**) using a BD FACSARIA™ Fusion Cell Sorter into ice cold 0.03% bovine serum albumin (BSA) in PBS. All isolated cells were immediately used for scRNA-seq libraries, which were generated as per the standard 10x Genomics Chromium 3' (v.3.1 Chemistry) protocol. Completed libraries were sequenced on a NextSeq5000 sequencer (HIGH-mode, 75 bp paired-end).

Sequenced transcripts were aligned to both human and mouse genomes (GRCh38 and mm10) and quantified into count matrices using Cellranger mkfastq and count workflows (10X Genomics, V 3.1.0, default parameters). The R package Seurat¹¹¹ (V 4.0.3) was used for QC of single cells and unsupervised clustering of the data. Briefly, human cells were separated from multiplets/mouse contamination based on >97 % of their reads aligning to GRCh38. Further filtering for high quality cells accepted only those with >200 but <20,000 total RNA counts and a percentage of mitochondrial reads <10%. Finally, remaining mouse transcripts were removed prior to further analysis. Normalisation, scaling and regression of mitochondrial read percentage was carried out using the scTransform package¹¹². Dimensionality reduction and differential expression analysis of identified clusters was performed using Seurat.

Single-cell gene signature scoring using UCell. The activity of the scNOVA-identified gene set from TALL-P1 in scRNA-seq data was profiled using the UCell package⁸². Briefly, signature genes considered were those with either increased (implying decreased expression) or decreased (implying increased expression) nucleosome occupancy (see **Fig. 5b**), or genes encoding TFs whose targets showed differential nucleosome occupancy (see **Fig. 5c**). The following gene set was used for T-ALL-P1: "PRKCB-", "RPS6KA2-", "FAM120B-", "FAM86C1+", "FBXO22+", "RHOH+", "SLC9A7+", "NASP+", "NOTCH1+", "MRPL48+", "MFSD9+", "MVB12B+", "MYB+" (with "+" for upregulated, and "-" for downregulated). The score per single cell for the entire directional gene set was calculated using the AddModuleScore_UCell() function. Cells were considered to be ‘active’ for the signature genes if their respective UCell score was greater than or equal to the median UCell score of the entire dataset, plus the standard deviation.

Fig. 1. scNOVA: Haplotype-aware single-cell multiomics to functionally characterize SVs. (a) Leveraging Strand-seq, the scNOVA framework discovers haplotype-phased SVs by performing single-cell tri-channel processing (scTRIP)²⁸, and then generates, in the same single cell, phased nucleosome occupancy (NO) tracks to allow SV functional characterization. Orange: Strand-seq reads mapped to the W (Watson) strand; green: C (Crick) strand. (b) Strand-seq based NO tracks in NA12878 reveal nucleosome positions highly concordant with high-coverage bulk MNase-seq, depicted for a chromosome 12 locus with regular nucleosome positioning¹¹³. Red: NO tracks mapping to haplotype 1 (H1); blue: H2; black: NO measured by combining phased and unphased Strand-seq reads; grey: MNase-seq. The y-axis depicts read counts at each base pair in 10bp bins. (c) Correlated NO at consensus DNase I hypersensitive sites³⁵, shown for NA12878. (d) Averaged nucleosome patterns at bound CTCF binding sites³⁴ in NA12878, using pseudo-bulk Strand-seq and bulk MNase-seq. (e) Pseudo-bulk haplotype-phased NO tracks based on Strand-seq, depicting a previously defined CRE³⁶ in NA12878 with haplotype-specific absence of NO on H1 (10% FDR). Bar chart on the right shows the allele-specific expression on H1 of *NFIB* – the inferred target gene of this CRE. Total: aggregated phased and unphased Strand-seq reads. (f) Inverse correlation of NO at gene bodies and bulk RNA-seq expression values. NO is based on pseudo-bulk Strand-seq libraries from RPE-1. RPM: reads per million. TTS: transcription termination site. To facilitate visualisation, gene bodies were scaled to the same length. (g) Cell type classification based on NO at gene bodies (AUC=0.96). Cell line codes: Blue: RPE-1. Purple: BM510. Magenta: C7. LV: latent variable. (h) Receiver operating characteristics for inferring altered gene activity based on analyzing NO at gene bodies, using pseudo-bulk Strand-seq libraries from *in silico cell* mixing. Ground truth sets of differentially active genes are based on bulk RNA-seq; performance was estimated for the top 10 and top 50 most differentially active genes, using scNOVA. The computed mean AUC was 0.93 for the top 10 genes (0.88 for the top 50 genes).

Fig. 2. Functional outcome of subclonal SV heterogeneity in lymphoblastoid cell lines (LCLs). (a) Complex, BFB-mediated rearrangements in NA20509 (17p) and terminal dispersed duplication (5q) present with CF=85%, here shown for representative single cells. Ref: normal chromosome. InvDup: inverted duplication. DelTer: terminal deletion. Reads denoting somatic SVs, discovered using scTRIP²⁸, map to the W (Watson, orange) or C (Crick, green) strand. Grey: single cell IDs. (b) Heatmap of 18 genes with inferred altered gene activity amongst subclones, using scNOVA (cells denoted 'chr5, 17 SVs' refers to the subclone bearing the complex SVs). (c) Gene set overrepresentation analysis for TF target genes showing significant enrichment of c-Myc and Max targets in the subclone bearing complex SVs. Right panel: Model for c-Myc/Max target activation in NA20509 based on scNOVA, combined with prior knowledge. (d) Mean RNA expression Z-scores of c-Myc/Max target genes across 33 LCLs. (e) Haplotype resolved RNA-seq read counts at heterozygous SNP sites within the *MAP2K3* gene locus, revealing monoallelic expression from the rearranged (BFB) haplotype (FDR-adjusted $P=1.1 \times 10^{-73}$; likelihood ratio test).

Fig. 3. Subclonal SVs in chronic lymphocytic leukemia (CLL) associated with aberrant Wnt signaling. (a) Single-cell SV discovery in CLL_24, revealing a diversity of subclonal deletions at chromosome 10q24.32 (all cells exhibiting deletions shown in Fig. S16). (b) Single cell breakpoint analysis reveals a minimally deleted segment (chr10:101615000-103028000; hg38), which displays recurring deletions in a separate cohort of CLLs (ICGC samples). (c) Heatmap of genes altered in activity in cells bearing 10q24.32 deletions, using scNOVA (10% FDR). (d) Inference of subclonal gene activity changes in CLL_24 for *DNM2*. 'Normal' indicates normal karyotype. C1, C2 and C3 denote subclones harboring deletions (Del) in the 'minimal region' at 10q24.32. S combines four single cells that exhibit individual deletions in the same minimal region (seen in $N=1$ cell each). (e) Pathway modules with differential activity, in cells exhibiting 10q24.32 deletions versus cells bearing a normal 10q (10% FDR). (f) Bulk RNA-seq analysis in 42 CLLs. Mean expression Z-scores for canonical Wnt signaling target genes are shown for each donor (green: CLL_24). (g-h) Minimal segment deletion-bearing (SV) CLL samples from the ICGC demonstrate overexpression of *DNM2* and Wnt signaling target genes compared to CLLs not bearing such SV (Normal) ($P=0.0098$; likelihood ratio test).

Fig. 4. Haplotype-specific NO patterns in *RUNX1-RUNX1T1* driven acute myeloid leukaemia (AML). (a) Balanced t(8;21) translocation in AML_1, discovered based on strand co-segregation (P -value for translocation discovery using strand co-segregation²⁸: $P=0.00003$, FDR-adjusted Fisher's exact test, Fig. S22). SV breakpoints were fine-mapped to the region highlighted in light blue. (b) A violin plot demonstrates haplotype-specific NO at the *RUNX1T1* gene body (10% FDR), consistent with aberrant activity of the locus on der(8). Haplotype-specific NO additionally found at the *ARFGEF1*, *NPR2*, and *SLC3A2* was shown next to it (10% FDR). (c) Haplotype-specific NO around the SV breakpoint. Fold changes of haplotype-specific NO, measured between the *RUNX1-RUNX1T1* containing derivative chromosome (der(8)) and corresponding regions on the unaffected homologue (Normal), are shown in black, and $-\log_{10}(P\text{-value})$ in light blue. Enhancer-target gene physical interactions based on chromatin conformation capture^{76,114} are depicted in orange (interactions involving *RUNX1* and *RUNX1T1*) and grey (involving other loci). (d) Significant CREs located within the distal peak region, demonstrating haplotype-specific absence of NO on der(8) at 10% FDR, indicative for increased CRE accessibility on der(8). (e) Haplotype-specific NO measured between der(8) and corresponding regions of the unaffected homologue. Red: regions corresponding to the fused TAD. A beeswarm plot shows that the fused TAD (red) is an outlier in terms of haplotype-specific NO on der(8) (P -values based on KS tests).

active for the signature genes of the chromothriptic (CT) subclone were shown in red. **(h)** Upper panel: Dot plot shows the significance of over-representation of scRNA-seq based SCNA calls in each of the clusters. Dot color indicates the significance score ($-\log_{10}$ adjusted P) from Fisher's exact test, and the dot sizes denote the cell fraction (CF) of having SCNA calls in each cluster. Cluster 3 and Cluster 7 were significantly overrepresented for scRNA-seq based SCNA calls (P -values based on FDR-adjusted Fisher exact tests). Lower panel: Dot plot for the scRNA-seq based gene set level expression summary for the 12 genes from panel (b). Dot color shows the relative UCell score per cluster, and dot size the percent of cells with scorable expression of the geneset. Gene set level expression was derived using UCell⁸² with the directionality of expression changes taken into account. **(i)** Bar graph showing P -values for the top 10 significant TFs from the TF-target over-representation analysis of differentially expressed genes for cluster 3. Red color denotes *MYB*, blue color denotes TFs which interact with/are transactivated by *MYB*. (For the corresponding P -values in cluster 7, where *MYB* was also significant, see **Table S10**).

References

1. Priestley, P. *et al.* Pan-cancer whole-genome analyses of metastatic solid tumours. *Nature* (2019) doi:10.1038/s41586-019-1689-y.
2. ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. *Nature* **578**, 82–93 (2020).
3. D'Entro, S. C. *et al.* Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes. *Cell* (2021) doi:10.1016/j.cell.2021.03.009.
4. Minussi, D. C. *et al.* Breast tumours maintain a reservoir of subclonal diversity during expansion. *Nature* **592**, 302–308 (2021).
5. Li, Y. *et al.* Patterns of somatic structural variation in human cancer genomes. *Nature* **578**, 112–121 (2020).
6. Watkins, T. B. K. *et al.* Pervasive chromosomal instability and karyotype order in tumour evolution. *Nature* (2020) doi:10.1038/s41586-020-2698-6.
7. Viswanathan, S. R. *et al.* Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing. *Cell* **174**, 433–447.e19 (2018).
8. McPherson, A. *et al.* Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer. *Nat. Genet.* **48**, 758–767 (2016).
9. Stephens, P. J. *et al.* Massive genomic rearrangement acquired in a single catastrophic event during cancer development. *Cell* **144**, 27–40 (2011).
10. Rausch, T. *et al.* Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. *Cell* **148**, 59–71 (2012).
11. Baca, S. C. *et al.* Punctuated evolution of prostate cancer genomes. *Cell* **153**, 666–677 (2013).

12. Umbreit, N. T. *et al.* Mechanisms generating cancer genome complexity from a single cell division error. *Science* **368**, (2020).
13. Hadi, K. *et al.* Distinct Classes of Complex Structural Variation Uncovered across Thousands of Cancer Genome Graphs. *Cell* **183**, 197–210.e32 (2020).
14. Northcott, P. A. *et al.* Enhancer hijacking activates GF11 family oncogenes in medulloblastoma. *Nature* **511**, 428–434 (2014).
15. Weischenfeldt, J. *et al.* Pan-cancer analysis of somatic copy-number alterations implicates IRS4 and IGF2 in enhancer hijacking. *Nat. Genet.* **49**, 65–74 (2017).
16. Liu, Y. *et al.* Discovery of regulatory noncoding variants in individual cancer genomes by using cis-X. *Nat. Genet.* (2020) doi:10.1038/s41588-020-0659-5.
17. PCAWG Transcriptome Core Group *et al.* Genomic basis for RNA alterations in cancer. *Nature* **578**, 129–136 (2020).
18. Dey, S. S., Kester, L., Spanjaard, B., Bienko, M. & van Oudenaarden, A. Integrated genome and transcriptome sequencing of the same cell. *Nat. Biotechnol.* **33**, 285–289 (2015).
19. Macaulay, I. C. *et al.* G&T-seq: parallel sequencing of single-cell genomes and transcriptomes. *Nat. Methods* **12**, 519–522 (2015).
20. Yin, Y. *et al.* High-Throughput Single-Cell Sequencing with Linear Amplification. *Mol. Cell* **76**, 676–690.e10 (2019).
21. Nam, A. S., Chaligne, R. & Landau, D. A. Integrating genetic and non-genetic determinants of cancer evolution by single-cell multi-omics. *Nat. Rev. Genet.* (2020) doi:10.1038/s41576-020-0265-5.
22. Nam, A. S. *et al.* Somatic mutations and cell identity linked by Genotyping of Transcriptomes. *Nature* **571**, 355–360 (2019).
23. Cortés-Ciriano, I. *et al.* Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing. *Nat. Genet.* **52**, 331–341 (2020).
24. Sanders, A. D., Falconer, E., Hills, M., Spierings, D. C. J. & Lansdorp, P. M. Single-cell template strand sequencing by Strand-seq enables the characterization of individual homologs. *Nat. Protoc.* **12**, 1151–1176 (2017).
25. Schones, D. E. *et al.* Dynamic regulation of nucleosome positioning in the human genome. *Cell* **132**, 887–898 (2008).

26. Lai, B. *et al.* Principles of nucleosome organization revealed by single-cell micrococcal nuclease sequencing. *Nature* **562**, 281–285 (2018).
27. Struhl, K. & Segal, E. Determinants of nucleosome positioning. *Nat. Struct. Mol. Biol.* **20**, 267–273 (2013).
28. Sanders, A. D. *et al.* Single-cell analysis of structural variations and complex rearrangements with tri-channel processing. *Nat. Biotechnol.* (2020) doi:10.1038/s41587-019-0366-x.
29. Teif, V. B. *et al.* Genome-wide nucleosome positioning during embryonic stem cell development. *Nat. Struct. Mol. Biol.* **19**, 1185–1192 (2012).
30. Lam, F. H., Steger, D. J. & O'Shea, E. K. Chromatin decouples promoter threshold from dynamic range. *Nature* **453**, 246–250 (2008).
31. Shivaswamy, S. *et al.* Dynamic remodeling of individual nucleosomes across a eukaryotic genome in response to transcriptional perturbation. *PLoS Biol.* **6**, e65 (2008).
32. Porubský, D. *et al.* Direct chromosome-length haplotyping by single-cell sequencing. *Genome Res.* **26**, 1565–1574 (2016).
33. Kundaje, A. *et al.* Ubiquitous heterogeneity and asymmetry of the chromatin environment at regulatory elements. *Genome Res.* **22**, 1735–1747 (2012).
34. ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. *Nature* **489**, 57–74 (2012).
35. Roadmap Epigenomics Consortium *et al.* Integrative analysis of 111 reference human epigenomes. *Nature* **518**, 317–330 (2015).
36. Wang, X. *et al.* High-resolution genome-wide functional dissection of transcriptional regulatory regions and nucleotides in human. *Nat. Commun.* **9**, 5380 (2018).
37. Giorgetti, L. *et al.* Structural organization of the inactive X chromosome in the mouse. *Nature* **535**, 575–579 (2016).
38. Satpathy, A. T. *et al.* Massively parallel single-cell chromatin landscapes of human immune cell development and intratumoral T cell exhaustion. *Nat. Biotechnol.* **37**, 925–936 (2019).
39. Yates, A. D. *et al.* Ensembl 2020. *Nucleic Acids Res.* **48**, D682–D688 (2020).
40. Mardin, B. R. *et al.* A cell-based model system links chromothripsis with hyperploidy. *Mol. Syst. Biol.* **11**, 828 (2015).
41. Ebert, P. *et al.* Haplotype-resolved diverse human genomes and integrated analysis of structural

- variation. *Science* (2021) doi:10.1126/science.abf7117.
42. Shirley, M. D. *et al.* Chromosomal variation in lymphoblastoid cell lines. *Hum. Mutat.* **33**, 1075–1086 (2012).
43. Zook, J. M. *et al.* An open resource for accurately benchmarking small variant and reference calls. *Nat. Biotechnol.* **37**, 561–566 (2019).
44. 1000 Genomes Project Consortium *et al.* A global reference for human genetic variation. *Nature* **526**, 68–74 (2015).
45. Mraz, M. *et al.* The origin of deletion 22q11 in chronic lymphocytic leukemia is related to the rearrangement of immunoglobulin lambda light chain locus. *Leuk. Res.* **37**, 802–808 (2013).
46. Dang, S. *et al.* Dynamic expression of ZNF382 and its tumor-suppressor role in hepatitis B virus-related hepatocellular carcinogenesis. *Oncogene* **38**, 4804–4819 (2019).
47. Li, Z. *et al.* A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells. *Proc. Natl. Acad. Sci. U. S. A.* **100**, 8164–8169 (2003).
48. Marinov, G. K. *et al.* From single-cell to cell-pool transcriptomes: stochasticity in gene expression and RNA splicing. *Genome Res.* **24**, 496–510 (2014).
49. Li, H. *et al.* Reference component analysis of single-cell transcriptomes elucidates cellular heterogeneity in human colorectal tumors. *Nat. Genet.* **49**, 708–718 (2017).
50. Patel, A. P. *et al.* Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. *Science* **344**, 1396–1401 (2014).
51. Fan, J. *et al.* Linking transcriptional and genetic tumor heterogeneity through allele analysis of single-cell RNA-seq data. *Genome Res.* **28**, 1217–1227 (2018).
52. Müller, S., Cho, A., Liu, S. J., Lim, D. A. & Diaz, A. CONICS integrates scRNA-seq with DNA sequencing to map gene expression to tumor sub-clones. *Bioinformatics* **34**, 3217–3219 (2018).
53. Byrska-Bishop, M. *et al.* High coverage whole genome sequencing of the expanded 1000 Genomes Project cohort including 602 trios. *BioRxiv* 2021.02.06.430068 (2021) doi:10.1101/2021.02.06.430068.
54. Kuleshov, M. V. *et al.* Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. *Nucleic Acids Res.* **44**, W90–7 (2016).
55. Bouchard, C., Staller, P. & Eilers, M. Control of cell proliferation by Myc. *Trends Cell Biol.* **8**, 202–206 (1998).

56. Nair, S. K. & Burley, S. K. X-ray structures of Myc-Max and Mad-Max recognizing DNA. Molecular bases of regulation by proto-oncogenic transcription factors. *Cell* **112**, 193–205 (2003).
57. Coulthard, L. R., White, D. E., Jones, D. L., McDermott, M. F. & Burchill, S. A. p38(MAPK): stress responses from molecular mechanisms to therapeutics. *Trends Mol. Med.* **15**, 369–379 (2009).
58. Ivanov, A. A. *et al.* OncoPPI-informed discovery of mitogen-activated protein kinase kinase 3 as a novel binding partner of c-Myc. *Oncogene* **36**, 5852–5860 (2017).
59. Döhner, H. *et al.* Genomic aberrations and survival in chronic lymphocytic leukemia. *N. Engl. J. Med.* **343**, 1910–1916 (2000).
60. Hewett, D. R. *et al.* FRA10B structure reveals common elements in repeat expansion and chromosomal fragile site genesis. *Mol. Cell* **1**, 773–781 (1998).
61. Edelmann, J. *et al.* High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations. *Blood* **120**, 4783–4794 (2012).
62. Puente, X. S. *et al.* Non-coding recurrent mutations in chronic lymphocytic leukaemia. *Nature* **526**, 519–524 (2015).
63. Malek, S. N. The biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemia. *Oncogene* **32**, 2805–2817 (2013).
64. Edelmann, J. *et al.* Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcription. *Haematologica* **105**, 1379–1390 (2020).
65. Ghamlouch, H., Nguyen-Khac, F. & Bernard, O. A. Chronic lymphocytic leukaemia genomics and the precision medicine era. *Br. J. Haematol.* **178**, 852–870 (2017).
66. Ge, Z. *et al.* Targeting High Dynamin-2 (DNM2) Expression by Restoring Ikaros Function in Acute Lymphoblastic Leukemia. *Sci. Rep.* **6**, 38004 (2016).
67. Liberzon, A. *et al.* Molecular signatures database (MSigDB) 3.0. *Bioinformatics* **27**, 1739–1740 (2011).
68. Boon, E. M. J., van der Neut, R., van de Wetering, M., Clevers, H. & Pals, S. T. Wnt signaling regulates expression of the receptor tyrosine kinase met in colorectal cancer. *Cancer Res.* **62**, 5126–5128 (2002).
69. Staal, F. J. T., Famili, F., Garcia Perez, L. & Pike-Overzet, K. Aberrant Wnt Signaling in Leukemia. *Cancers* **8**, (2016).

70. Ianakiev, P. *et al.* A novel human gene encoding an F-box/WD40 containing protein maps in the SHFM3 critical region on 10q24. *Biochem. Biophys. Res. Commun.* **261**, 64–70 (1999).
71. Reifemberger, J. *et al.* Molecular genetic analysis of malignant melanomas for aberrations of the WNT signaling pathway genes CTNNB1, APC, ICAT and BTRC. *Int. J. Cancer* **100**, 549–556 (2002).
72. Erickson, P. *et al.* Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. *Blood* **80**, 1825–1831 (1992).
73. Xiao, Z. *et al.* Molecular characterization of genomic AML1-ETO fusions in childhood leukemia. *Leukemia* **15**, 1906–1913 (2001).
74. Abdul-Nabi, A. M., Yassin, E. R., Varghese, N., Deshmukh, H. & Yaseen, N. R. In vitro transformation of primary human CD34+ cells by AML fusion oncogenes: early gene expression profiling reveals possible drug target in AML. *PLoS One* **5**, e12464 (2010).
75. Bajaj, J. *et al.* CD98-Mediated Adhesive Signaling Enables the Establishment and Propagation of Acute Myelogenous Leukemia. *Cancer cell* vol. 30 792–805 (2016).
76. Mifsud, B. *et al.* Mapping long-range promoter contacts in human cells with high-resolution capture Hi-C. *Nat. Genet.* **47**, 598–606 (2015).
77. Korbel, J. O. & Campbell, P. J. Criteria for inference of chromothripsis in cancer genomes. *Cell* **152**, 1226–1236 (2013).
78. Bhavsar, P. J., Infante, E., Khwaja, A. & Ridley, A. J. Analysis of Rho GTPase expression in T-ALL identifies RhoU as a target for Notch involved in T-ALL cell migration. *Oncogene* **32**, 198–208 (2013).
79. Ferrando, A. A. The role of NOTCH1 signaling in T-ALL. *Hematology Am. Soc. Hematol. Educ. Program* 353–361 (2009).
80. Onishi, I. *et al.* Organellar (Na⁺, K⁺)/H⁺ exchanger NHE7 regulates cell adhesion, invasion and anchorage-independent growth of breast cancer MDA-MB-231 cells. *Oncol. Rep.* **27**, 311–317 (2012).
81. Antal, C. E. *et al.* Cancer-associated protein kinase C mutations reveal kinase's role as tumor suppressor. *Cell* **160**, 489–502 (2015).
82. Andreatta, M. & Carmona, S. J. UCell: Robust and scalable single-cell gene signature scoring.

- Comput. Struct. Biotechnol. J.* **19**, 3796–3798 (2021).
83. Kumar, A., Lee, C. M. & Reddy, E. P. c-Myc is essential but not sufficient for c-Myb-mediated block of granulocytic differentiation. *J. Biol. Chem.* **278**, 11480–11488 (2003).
 84. Bianchi, E. *et al.* c-myb supports erythropoiesis through the transactivation of KLF1 and LMO2 expression. *Blood* **116**, e99–110 (2010).
 85. Street, K. *et al.* Slingshot: cell lineage and pseudotime inference for single-cell transcriptomics. *BMC Genomics* **19**, 477 (2018).
 86. Pattabiraman, D. R. & Gonda, T. J. Role and potential for therapeutic targeting of MYB in leukemia. *Leukemia* **27**, 269–277 (2013).
 87. Loh, P.-R. *et al.* Insights into clonal haematopoiesis from 8,342 mosaic chromosomal alterations. *Nature* **559**, 350–355 (2018).
 88. Zhu, C., Preissl, S. & Ren, B. Single-cell multimodal omics: the power of many. *Nat. Methods* **17**, 11–14 (2020).
 89. Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y. & Greenleaf, W. J. Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. *Nat. Methods* **10**, 1213–1218 (2013).
 90. Porubsky, D. *et al.* Fully phased human genome assembly without parental data using single-cell strand sequencing and long reads. *Nat. Biotechnol.* (2020) doi:10.1038/s41587-020-0719-5.
 91. Logsdon, G. A. *et al.* The structure, function and evolution of a complete human chromosome 8. *Nature* (2021) doi:10.1038/s41586-021-03420-7.
 92. Forsberg, L. A., Gisselsson, D. & Dumanski, J. P. Mosaicism in health and disease - clones picking up speed. *Nat. Rev. Genet.* **18**, 128–142 (2017).
 93. Leibowitz, M. L. *et al.* Chromothripsis as an on-target consequence of CRISPR-Cas9 genome editing. *Nat. Genet.* (2021) doi:10.1038/s41588-021-00838-7.
 94. Dietrich, S. *et al.* Drug-perturbation-based stratification of blood cancer. *J. Clin. Invest.* **128**, 427–445 (2018).
 95. Falconer, E. *et al.* DNA template strand sequencing of single-cells maps genomic rearrangements at high resolution. *Nat. Methods* **9**, 1107–1112 (2012).
 96. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* **25**, 1754–1760 (2009).

97. Boulesteix, A.-L. & Strimmer, K. Partial least squares: a versatile tool for the analysis of high-dimensional genomic data. *Brief. Bioinform.* **8**, 32–44 (2007).
98. McInnes, L., Healy, J. & Melville, J. UMAP: Uniform Manifold Approximation and Projection for Dimension Reduction. *arXiv [stat.ML]* (2018).
99. Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *J. R. Stat. Soc. Series B Stat. Methodol.* **57**, 289–300 (1995).
100. Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics* **26**, 139–140 (2010).
101. Ramírez, F. *et al.* deepTools2: a next generation web server for deep-sequencing data analysis. *Nucleic Acids Res.* **44**, W160–5 (2016).
102. Ulz, P. *et al.* Inferring expressed genes by whole-genome sequencing of plasma DNA. *Nat. Genet.* **48**, 1273–1278 (2016).
103. Eraslan, G., Avsec, Ž., Gagneur, J. & Theis, F. J. Deep learning: new computational modelling techniques for genomics. *Nat. Rev. Genet.* **20**, 389–403 (2019).
104. Heinz, S. *et al.* Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. *Mol. Cell* **38**, 576–589 (2010).
105. Haeussler, M. *et al.* The UCSC Genome Browser database: 2019 update. *Nucleic Acids Res.* **47**, D853–D858 (2019).
106. Dobin, A. *et al.* STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15–21 (2013).
107. Rausch, T., Hsi-Yang Fritz, M., Korb, J. O. & Benes, V. Alfred: interactive multi-sample BAM alignment statistics, feature counting and feature annotation for long- and short-read sequencing. *Bioinformatics* **35**, 2489–2491 (2019).
108. Bergstra, J., Yamins, D. & Cox, D. Making a Science of Model Search: Hyperparameter Optimization in Hundreds of Dimensions for Vision Architectures. in *Proceedings of the 30th International Conference on Machine Learning* (eds. Dasgupta, S. & McAllester, D.) vol. 28 115–123 (PMLR, 2013).
109. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* **15**, 550 (2014).
110. Schmitz, M. *et al.* Xenografts of highly resistant leukemia recapitulate the clonal composition of the leukemogenic compartment. *Blood* **118**, 1854–1864 (2011).

111. Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. *Nat. Biotechnol.* **36**, 411–420 (2018).
112. Hafemeister, C. & Satija, R. Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression. *Genome Biol.* **20**, 296 (2019).
113. Gaffney, D. J. *et al.* Controls of nucleosome positioning in the human genome. *PLoS Genet.* **8**, e1003036 (2012).
114. Fishilevich, S. *et al.* GeneHancer: genome-wide integration of enhancers and target genes in GeneCards. *Database* **2017**, (2017).